Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 1 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
 
Statistical Analysis Plan  
 
Sponsor:  Estetra  
Protocol No:  MIT-Es0001 -C302 
Version No./Date  Final 1.1/ 10-July-2017 
Title A Multicenter, Open -label, Single -Arm Study to Evaluate the  
Contraceptive Efficacy and Safety of a Combined Oral  
Contraceptive Contai ning 15 mg Estetrol and 3 mg Drospirenone  
Clinical Trials.gov 
regist ration N o. [STUDY_ID_REMOVED]  
CRF Version 
No./Date  3.0/18-July-2017 
PRA Project Id:  MHUEC302 -ESC302  
SAP Version  
No./Date:  3.0/11 Dec ember  2018  
Approvals  
Sponsor  
Sponsor Name:  Estetra SPRL  
Representative/ Title:  Sophie Ledant, Clinical Pro ject Leader  
Signature /Date:   
 
Sponsor Name:  Estetra SPRL  
Representative/ Title:  Marie Mawet, Medical Advisor  
Signature /Date:   
 
PRA  
Project Manager/Title:  La√´titia Poher, Project Director  
Signature /Date:   
 
Biostatistician / Title:  Jess Sadler , Senior Principal Biostatistician  
Signature /Date:   
 
  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 2 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
Table of Contents  
Approvals  ................................ ................................ ................................ ................................ ................................ ....................  1 
Table of Contents  ................................ ................................ ................................ ................................ ................................ ..... 2 
1.0 Introduction  ................................ ................................ ................................ ................................ ................................ ....... 5 
2.0 Study Objectives  ................................ ................................ ................................ ................................ ...............................  5 
2.1 Primary Objective  ................................ ................................ ................................ ................................ .......................  5 
2.2 Secondary Efficacy Objectives ................................ ................................ ................................ ................................  5 
2.3 Other Secondary Objectives  ................................ ................................ ................................ ................................ .... 5 
3.0 Study Design  ................................ ................................ ................................ ................................ ................................ ....... 5 
3.1 Sample Size Considerations  ................................ ................................ ................................ ................................ .... 6 
4.0 Study Variables and Covariates  ................................ ................................ ................................ ................................ .. 6 
4.1 Prima ry Variable ................................ ................................ ................................ ................................ ..........................  6 
4.2 Secondary Variables  ................................ ................................ ................................ ................................ ...................  7 
4.2.1 Efficacy  ................................ ................................ ................................ ................................ ................................ .... 7 
4.2.2 Othe r Secondary Variables  ................................ ................................ ................................ .............................  7 
4.3 Predetermined Subgroups  ................................ ................................ ................................ ................................ ...... 7 
5.0 Definitions  ................................ ................................ ................................ ................................ ................................ ...........  8 
5.1 Cycle  ................................ ................................ ................................ ................................ ................................ ..................  8 
5.1.1 At -risk Cycle for Pearl Index  ................................ ................................ ................................ ..........................  8 
5.1.2 Evaluable Cycle and Reference Period for Bleeding Data  ................................ ................................ .. 9 
5.2 Baseline and Change from Baseline  ................................ ................................ ................................ ...................  11 
5.3 On -Treatment Period  ................................ ................................ ................................ ................................ ...............  11 
5.4 Body Ma ss Index  ................................ ................................ ................................ ................................ ........................  11 
5.5 Switchers, Starters and True New Users  ................................ ................................ ................................ .........  11 
5.6 Prior, Post -Study Treatment and Concomitant Medication Use  ................................ ............................  12 
5.7 Study Treatment Compliance  ................................ ................................ ................................ ...............................  12 
5.7.1 Compliance analysis by cycle  ................................ ................................ ................................ .......................  12 
5.7.2 Overall compliance  ................................ ................................ ................................ ................................ ...........  13 
5.8 Extent of Exposure  ................................ ................................ ................................ ................................ ....................  13 
5.9 Pregnancy Related Definitions  ................................ ................................ ................................ ............................  14 
5.9.1 Pre -Treatment Pregnancies ................................ ................................ ................................ ..........................  14 
5.9.2 On -Treatment Pregnancies  ................................ ................................ ................................ ...........................  14 
5.9.3 Post -Treatment Pregnancies  ................................ ................................ ................................ ........................  14 
5.9.4 Method and User Failure Pregnancies  ................................ ................................ ................................ ..... 14 
5.10 Bleeding Patterns  ................................ ................................ ................................ ................................ ...................  15 
5.10.1 Definitions of Bleeding and Spotting ................................ ................................ ................................ ...... 15 
5.10.2 Cycle analysis  ................................ ................................ ................................ ................................ ...................  15 
5.10.3 Reference Periods (RPs)  ................................ ................................ ................................ ..............................  17 
5.10.4 Bleeding Endpoints for the Cycle Analysis  ................................ ................................ ..........................  17 
5.10.5 Bleeding Endpoints for Analyses by RP  ................................ ................................ ................................  19 
5.11 Treatment -Emergent Adverse Event (TEAE)  ................................ ................................ .............................  19 
5.12 Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q -LES-Q-SF) ...............  19 
5.13 Menstrual Distress Questionnaire  ................................ ................................ ................................ ...................  20 
5.14 Return to Fertility  ................................ ................................ ................................ ................................ ...................  20 
5.15 Methods for Handling Missing Data  ................................ ................................ ................................ ................  20 
5.15.1 Missing Data Related to the Pearl Index and Pill Intake  ................................ ................................  20 
5.15.2 Missing Bleeding Data  ................................ ................................ ................................ ................................ .. 21 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 3 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
5.15.3 Missing or Partial Dates for Medications  ................................ ................................ .............................  21 
5.15.4 Missing or Partial Dates for AEs  ................................ ................................ ................................ ...............  22 
5.15.5  Missing or Partial Treatment Start and Stop Dates  ................................ ................................ .........  22 
6.0 Analysis Sets  ................................ ................................ ................................ ................................ ................................ ..... 23 
6.1 Screened Population  ................................ ................................ ................................ ................................ ................  23 
6.2 Enrolled Population  ................................ ................................ ................................ ................................ .................  23 
6.3 Safety Population  ................................ ................................ ................................ ................................ ......................  23 
6.4 Intention -to-Treat (ITT) Population  ................................ ................................ ................................ .................  23 
6.5 Per -Protocol (PP) Population  ................................ ................................ ................................ ...............................  23 
6.6 Pharmacokinetics (PK) Population  ................................ ................................ ................................ ....................  23 
7.0 Interim Analyses  ................................ ................................ ................................ ................................ .............................  24 
8.0 Data Review  ................................ ................................ ................................ ................................ ................................ ...... 24 
8.1 Data Handling and Transfer  ................................ ................................ ................................ ................................ .. 24 
8.2 Data Screening  ................................ ................................ ................................ ................................ ............................  24 
8.3 Data Review Meetings  ................................ ................................ ................................ ................................ .............  24 
9.0 Statistical Methods  ................................ ................................ ................................ ................................ ........................  24 
9.1 Subject Disposition  ................................ ................................ ................................ ................................ ...................  25 
9.2 Protocol Deviations and Violations  ................................ ................................ ................................ ....................  25 
9.3 Treatments  ................................ ................................ ................................ ................................ ................................ ... 26 
9.3.1 Extent of Study Drug Exposure  ................................ ................................ ................................ ...................  26 
9.3.2 Treatment Compliance  ................................ ................................ ................................ ................................ ... 26 
9.3.3 Prior,  Post -Study Treatment and Concomitant Medications  ................................ ..........................  26 
9.4 Demographic and Baseline Characteristics  ................................ ................................ ................................ .... 26 
9.5 Efficacy Analyses  ................................ ................................ ................................ ................................ .......................  27 
9.5.1 Primary Variable  ................................ ................................ ................................ ................................ ...............  27 
9.5.2 Secondary Variables  ................................ ................................ ................................ ................................ ........  28 
9.5.3 Bleeding a nd Spotting  ................................ ................................ ................................ ................................ ..... 30 
9.6 Safety Analyses  ................................ ................................ ................................ ................................ ...........................  32 
9.6.1 Adverse Events  ................................ ................................ ................................ ................................ ..................  32 
9.6.2  Deaths and Serious Adverse Events  ................................ ................................ ................................ ..........  32 
9.6.3 Laboratory Data ................................ ................................ ................................ ................................ .................  33 
9.6.4 Vital Signs  ................................ ................................ ................................ ................................ .............................  34 
9.6.5 Physical and Gynecological Examinations  ................................ ................................ ..............................  34 
9.7 Other Secondary Endpoints (Excluding PK)  ................................ ................................ ................................ .. 34 
9.7.1 Quality of  Life ................................ ................................ ................................ ................................ .....................  34 
9.7.2 Follow -Up Evaluations ................................ ................................ ................................ ................................ .... 34 
9.8 Population Pharmacokinetics Analysis  ................................ ................................ ................................ ............  35 
9.8.1 Data Included in Analysis  ................................ ................................ ................................ ..............................  35 
9.8.2 Objectives  ................................ ................................ ................................ ................................ .............................  35 
9.8.3 Assumptions  ................................ ................................ ................................ ................................ .......................  35 
9.8.4 Prespecified Hypotheses  ................................ ................................ ................................ ................................  35 
9.8.5 Study MIT -Es0001 -C302  ................................ ................................ ................................ ................................  36 
9.8.6 Study Es0001 -C101 ................................ ................................ ................................ ................................ ..........  36 
9.8.7 Study MIT -Es0001 -C103  ................................ ................................ ................................ ................................  37 
9.8.8 Data management  ................................ ................................ ................................ ................................ .............  37 
9.8.9 Data Deletion  ................................ ................................ ................................ ................................ ......................  38 
9.8.10 PopPK Model Development  ................................ ................................ ................................ .......................  38 
9.8.11 PopPK Model Evaluation  ................................ ................................ ................................ .............................  39 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 4 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
9.8.12 Reporting  ................................ ................................ ................................ ................................ ...........................  39 
9.8.13 Source Files  ................................ ................................ ................................ ................................ .......................  40 
10.0 Validation  ................................ ................................ ................................ ................................ ................................ ........  41 
11.0 R eferences  ................................ ................................ ................................ ................................ ................................ ...... 41 
12.0 Amendment to the Statistical Analysis Plan  ................................ ................................ ................................ ..... 41 
12.1 Amendment 1 from SAP dated 12 December 2016 ................................ ................................ ..................  41 
12.2 Amendment 2 from SAP dated 13 November 2018  ................................ ................................ .................  43 
Appendix 1 Glossary of Abbreviations  ................................ ................................ ................................ .........................  44 
 
 
 
 
 
  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 5 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
1.0 Introduction  
This statistical analysis plan (SAP) describes the statistical methods to be used during the reporting and 
analyses of data collected under Estetra  Protocol MIT-Es0001 -C302.  
This SAP should be read in conjunction with the study protocol and case report fo rm (CRF). This version 
of the plan has been developed using the protocol  amendment 1.1  dated 10 July  2017 and CRF  version 
3.0 dated 18 July 2017. Any further changes to the protocol or CRF may necessitate updates to the SAP.  
2.0 Study Objectives  
2.1 Primary Object ive 
The primary objective of this study is to evaluate the contraceptive efficacy of 15 mg Estetrol (E4)/3 mg 
Drospirenone (DRSP) using the Pearl Index in subjects aged 16 to 35 years, inclusive, at the time of 
screening.  
2.2 Secondary Efficacy Objectives  
The secondary objectives of this study are:  
1. To evaluate the contraceptive efficacy of 15 mg E4/3 mg DRSP using the method failure Pearl 
Index and life -table analysis in subjects aged 16 to 35 years, inclusive, at the time of screening  
2. To evaluate the contracep tive efficacy of 15 mg E4/3 mg DRSP using the Pearl Index, the method 
failure Pearl Index and life -table analysis in the overall study population  
2.3 Other Secondary Objectives  
1. To evaluate cycle control and bleeding pattern associated with 15 mg E4/3 mg DRSP  
2. To evaluate general safety of 15 mg E4/3 mg DRSP  
3. To evaluate the impact of 15 mg E4/3 mg DRSP on physical, psychological, and social functioning 
and well -being  
4. To assess the effect of various individual characteristics/covariates ( e.g., body weight, race, a nd 
smoking) on the pharmacokinetics (PK) of 15  mg E4/3 mg DRSP (Population PK Substudy)  
3.0 Study Design  
This study is a multicenter, open -label, single -arm study.  
The total duration of the study, including the screening, will range from 382 to 447 days for mo st of the 
subjects, which is approximately 13 -15 months. Those subjects who discontinue and desire pregnancy will 
be followed for a maximum of one year after study discontinuation for return of spontaneous menstruation 
and until pregnancy or initiation of a contraceptive method (whichever occurs first).  
Approximately 2000 healthy female subjects at-risk for pregnancy, between 16 and 50 years old (inclusive, 
at the time of screening), and requesting contraception will be enrolled in the study. In total 1800 subjects 
will be 16 to 35 years old (inclusive). Recruitment may be stopped when 2000 subjects have been enrolled 
if the required number of subjects for the primary analysis (1800 subjects in the age group up to 35 years) 
has been reached. Recruitment of women aged 36 -50 years will be stopped when 200 subjects  in this age 
range  have been enrolled.  
Eligible subjects will be treated with 15 mg E4/3 mg DRSP for up to maximum of 13 consecutive cycles. 
The treatment must be taken once daily at approximately the  same time of the day in a 24/4 -day regimen, 
i.e. 24 active tablets followed by 4 placebo tablets (4 -day hormone free interval).  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 6 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
The primary study objective is to evaluate the contraceptive efficacy of the new Combined Oral 
Contraceptive (COC), using the P earl Index calculation (which reflects the pregnancy rate associated with 
a contraceptive method) among the subjects aged 16 to 35 years inclusive.  
The contraceptive efficacy will also be evaluated using the method failure Pearl Index (which reflects the 
pregnancy rate due to method failure only) and life -table analysis in the subjects aged 16 to 35 years 
inclusive and in the overall study population.  
The general safety will be evaluated by the determination of routine laboratory parameters, vital signs, by  
performing physical, gynecological and breast examinations and by recording number, frequency, type and 
intensity of adverse events (AEs) and serious adverse events (SAEs).  
Participating subjects will be asked to record daily in a subject diary their blee ding/spotting episodes. This 
will allow evaluating the bleeding pattern and the cycle control associated with the investigational product.  
Treatment compliance will be assessed using data from the subject diary across the entire study and by 
cycle  and, in the case of a pregnancy, detailed information from a pregnancy narrative completed by the 
site Principal Investigator.  The subject diary will also be used to determine whether or not a cycle is an at-
risk cycle for the Pearl Index calculation. In the prima ry analysis of the Pearl Index, at-risk cycles will be 
defined as cycles in which the following criteria are met:  
1. No other methods of birth control (including condoms  and emergency contraception ) are used by 
the subject as confirmed in the subject diary  
2. The subject confirmed that sexual intercourse occurred during the cycle in the subject diary  
Note that if conception occurs in a cycle, then that cycle will be included as an at-risk cycle in the 
denominator even if any other contraceptive method was used d uring that cycle or the subject did not 
confirm that sexual intercourse occurred. Cycles after the cycle of conception will not be included as at-risk 
cycles and will be excluded from the denominator.  
Physical, psychological and social functioning and well -being associated with the investigational product 
will be assessed with well -established questionnaires. A study schedule of events is provided in Appendix 
1 of the Protocol. Population PK will be assessed using plasma E4 and DRSP concentration data from a 
subset of approximately 500 subjects to evaluate the relationship between E4 and DRSP PK parameters 
and various characteristics (e.g., body weight, race, and smoking). Blood samples for PK analysis will be 
obtained at Visits 3 and 4 between Days 10 and 1 4 of Cycles 2 and 4.   
3.1 Sample Size Considerations  
Sample size is based on  the need to have a sufficient number of cycles such that the difference between 
the Pearl Index and the  upper limit of the two -sided 95% confidence interval (CI) for the Pearl Index d oes 
not exceed 1. Assuming that the true Pearl Index is 1.0 and that a Poisson model is used to derive the CIs, 
then at least 12,337 at-risk cycles are required for a power of 90% in the 16 to 35 year old population  
(Gerlinger  et al., 2003 ).  
Assuming 80% of the study cycles are at-risk cycle and a dropout rate of approximately 45% (assuming 
that we have an average of 4 cycles for subjects that discontinue) are assumed, approximately 1800 16 -
to-35 year old subjects need to be enrolled. Additionally, it is planned to enroll a maximum of 200 subjects 
36-50 years. Therefore, in total, approximately 2000 subjects will be enrolled in the study. Additionally, a 
subset of approximately 500 subjects will be enrolled in the PK Substudy.   
4.0 Study Variables and Covariates  
4.1 Primary Variable  
The primary efficacy variable will be the number of on -treatment pregnancies assessed by the Pearl Index 
in the ITT population aged 16 to 35 years, inclusive, at the time of screening with at-risk cycles (c ycles in 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 7 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
which no other methods of birth control (including condoms and emergency contraception)  are used and 
during which the subjects confirmed that sexual intercourse has occurred).  
4.2 Secondary Variables  
4.2.1  Efficacy  
The secondary efficacy variables are:  
1. The number of on -treatment pregnancies as assessed by the method failure Pearl Index and the 
cumulative pregnancy rate in subjects aged 16 to 35 years, inclusive, at the time of screening  
2. The number of on -treatment pregnancies as assessed by the Pearl Index, t he method failure Pearl 
Index and the cumulative pregnancy rate in the overall study population  
4.2.2  Other Secondary Variables  
The other secondary variables are:  
1. Cycle control and bleeding patterns based on vaginal bleeding information recorded daily by the 
subjects in the diaries  
2. Safety data in the overall study population obtained from routine laboratory parameters, vital signs, 
and physical, gynecological and breast examinations, evaluated as the number, frequency, type 
and intensity of AEs and SAEs  
3. Change f rom baseline to end of treatment in the different items of well -established questionnaires 
to evaluate physical, psychological, and social functioning and well -being  
4. Plasma E4 and DRSP concentration data from a subset of approximately 500 subjects for the 
development of a population PK model (Population PK Substudy). PK parameters will include, but 
not be limited to:  
a. Apparent clearance (CL/F).  
b. Central volume of distribution (V/F).  
c. Lag time of Absorption ( Tlag), if necessary.  
d. Maximum concentration (Cmax).  
e. Time to Cmax (Tmax).  
f. Extent of exposure for the dosing interval (AUCtau).  
g. Terminal half -life (t ¬Ω). 
4.3 Predetermined Subgroups  
The key subgroup in this study is subjects aged 16 to 35 years, inclusive, at the time of screening. This 
subgroup is used for the prim ary efficacy population. All data regarding disposition, baseline characteristic s, 
compliance, exposure and contraceptive efficacy will be presented for subjects aged 16 to 35 years and for 
all subjects within the specified analysis population.  
In additio n, subgroup analyses will be performed for the Pearl Index and bleeding data (specifically 
unscheduled bleeding and spotting and the absence of scheduled bleeding) for the following categories:  
ÔÇ∑ Body Mass Index (BMI) categories (< 30, ‚â• 30  kg/m2) at Baseline  
ÔÇ∑ Race category (White, Black or African American, Asian, American Indian or Alaska Native, Native 
Hawaiian or other Pacific Islander, Other Race)  
ÔÇ∑ Starters (including true new users)/ Switchers (see Section 5.5) 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 8 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
ÔÇ∑ Smokers/Non -smokers at Baseline  
ÔÇ∑ Age ( ‚â• 16 to ‚â§ 25; > 25 to ‚â§ 35 and > 35 years old) at Screening  
The non -smokers group includes subjects who are former smokers and never smokers. The smokers gro up 
includes subjects who are current smokers. The other race group includes subjects who selected more 
than one race or whose race was recorded as other race  on the CRF .  
Quality of life data will be presented for all subjects and for starters and switcher s separately.  
5.0 Definitions  
5.1 Cycle  
The expected duration of a cycle is  28 days.  A 28 -day cycle consists of 24 days of active tablet intake 
followed by 4 days of inactive tablet intake and subject s who complete the study are expected to have 
completed thirteen  28-day cycles.  
All cycles will be determined using the start dates recorded in the diaries. The first day of a cycle is the start 
date recorded on the diary for that cycle and the last day of a cycle coincides with the day before the start 
date recorded o n the diary for the next cycle. However, because the last cycle of use has no start date for 
a following cycle, the last day of the cycle will be assumed to be the date of last dose of study medication , 
whether this is an active or inactive tablet . The dat e of last dose of study medication in the last cycle will be 
derived from the data collected in the diary . 
If the conception is confirmed to be during a specific cycle in the narrative and this cycle is not in the diary 
data, then the cycle will be include d as cycle in the exposure for the derivation of the Pearl Index.  If the 
cycle in which conception occurred i s not known, cycle(s) up to the one in which the positive pregnancy 
test occurred will be included in the exposure for the derivation of the Pearl Index.  
For the analysis of bleeding data, the cycle will be shifted by 3 days with the 3 days of the next cycle 
included in the previous cycle. For example, in the bleeding analysis Cycle 2 will be from Day 4 of Cycle 2 
to Day 3 of Cycle 3 inclusive.   
The start and stop times of a cycle will be determined before determining whether the cycle is evaluable for 
the Pearl Index or evaluable for the bleeding data. Data review meetings may be held to determine if cycles 
are at-risk cycles  for the Pearl Index and if they are evaluable for the bleeding analysis prior to database 
lock (see Section 8.3) if the classification is not clear from  the data collected and the rules in the SAP .  
5.1.1  At-risk Cycle for Pearl Index   
In the  primary  calcul ation of the Pearl Index (see Section 9.5.1  for details)  and the Method failure Pearl 
Index , only at-risk cycles will be included in the derivation of the number of women -28 day equivalent cycles 
of treatment, which is used as the denominator. At-risk cycles will be defined as cycles in which the following 
criteria are both met: 
1. No other methods of birth control (including condoms and emergency contraception)  are used by 
the subject as confirmed in the subject diary  
2. The subject confirmed that sexual intercourse occurred during the cycle in the subject diary  
This definition of at-risk cycles will be used as the denominator for the Pearl Index for on -treatment 
pregnancies and also for on -treatment method failure pregnancies.  
Two alternative calculations of the exposure (i.e., the d enominator ) will be perfo rmed to allow  for 
comparisons with historical data : 
ÔÇ∑ All exposure,  which includes cycles with and without  other methods of birth control and cycles with 
and without sexual intercour se. In this derivation of the Pearl Index all cycles  are classed as at-
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 9 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
risk cycles with the exception of any cycles after the cycle of conception in the case of pregnancy . 
This denominator will be used for the Pearl Index for on -treatment pregnancies only , 
ÔÇ∑ Modified at-risk exposure, where only cycles with other methods of birth control are excluded, while 
occurrence  of sexual intercourse  is not taken into account . In this derivation of the Pearl Index, at-
risk cycles are defined as cycles in which no other methods of birth control (including condoms and 
emergency contraception)  are used by the subject as confirmed in the subject diary.  
Two additional alternative definition s of at-risk cycles will be used for  the derivation of the Pearl Index for 
method failu re pregnancies . In the first of these definitions,  cycles q ualify if they meet all of the criteria 1 to 
8 listed below :  
1. No other methods of birth control (including condoms and emergency contraception)  are used by 
the subject as confirmed in the subject d iary 
2. The subject confirmed that sexual intercourse occurred during the cycle in the subject diary  
3. A subject does not have a user failure pregnancy with an estimated conception date in that cycle 
or prior to that cycle  and does not have a method failure pre gnancy with an estimated conception 
date prior to that cycle   
4. The subject does not receive unauthorized concomitant medication (see section 9.4.6.1 of the 
protocol) for at least one day during the cycle  
5. The subject  does not  miss 4 or more days of active p ills during the cycle   
6. The subject does not miss 2 or more consecutive days of active pills during the cycle  
7. The length of the previous cycle is not longer than 28 days  
8. The subject had  no adverse events  of vomiting and/or diarrhea during the cycle  
In the s econd of these definitions, cycles qualify if they meet all of the criteria 1 and 3 to 8 listed above (i.e. 
occurrence of sexual intercourse is not taken into account),  
The following rules will be applied to all types of exposure :  
ÔÇ∑ If conception occurs in  a cycle, then that cycle will be included in the denominator , regardless of 
whether or not other  methods of birth control were used during that cycle , or whether or not sexual 
intercourse was confirmed .  
ÔÇ∑ If the conception is confirmed to be during a speci fic cycle in the narrative and this cycle is 
not in the diary data, then the cycle will be included  in the denominator , regardless of whether 
or not other methods of birth control were used during that cycle , or whether or not sexual 
intercourse was confir med  
ÔÇ∑ The only exception is for user failure pregnancies, which will be excluded from the exposure 
definitions based on the compliance rules 3 to 8 above, since they do not meet criterion 3  
ÔÇ∑ Cycles after the cycle of conception will be excluded from the deno minator  
ÔÇ∑ Missing data from the diary will be handled according to section 5.15.1 . 
5.1.2  Evaluable Cycle and Reference Period for Bleeding Data   
Bleeding data will be analyzed by cycle  and by  91-day reference period (RP) . For the analy sis of bleeding 
data by cycle , the cycle will be shifted by 3 days with the 3 days of the next cycle included in the previous 
cycle. For example, in the bleeding analysis Cycle 2 will be from Day 4 of Cycle 2 to Day 3 of Cycle 3 
inclusive.  For the 3 days a fter Cycle 13, the last non -missing response for bleeding  in Cycle 13  will be 
imputed.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 10 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
In determining whether a cycle is evaluable for the bleeding analysis of a specific population, the cycle 
based on the diary data will be used rather than the shifted cy cle used to present the data.  
For the ITT analysi s, a cycle wi ll be considered non -evaluable if:  
ÔÇ∑ The length of the cycle is longer than 28 days.  
A cycle will be considered non -evaluable  in the per -protocol (PP) analysis  for bleeding data  if any of the 
following criteria are met:  
1. A subject becomes pregnant in that cycle  or prior to that cycle  
2. The length of the cycle is shorter than 22 days or longer than 28 days  
3. A subject did not have a hormone -free period towards the end of the cycle  (i.e. there are not at 
least 4 days where an active tablet was not taken between the last day an active tablet was taken 
in this cycle and the first day an active tablet was taken in the next cycle)  
4. The subject received unauthorized  concomitant medication (see section 9.4.6.1  of the protocol)  
thought to have the potential to impact the bleeding analysis  for at least one day during the cycle  
5. Use of unauthorized pre-treatment and  concomitant medication  thought to have the potential to 
impact the bleeding analysis , if cycle star ts within 28 days after discontinuation of unauthorized 
medication  
6. The subject had a positive test for chlamydia or gonorrhea during that cycle  
7. The subject missed 4 or more days of active pills during the cycle  
8. The subject missed 2 or more consecutive days  of active pills during the cycle  
9. The subject had a procedure to the vagina , cervix  or endometrium during the cycle  
A cycle with missing diary bleeding data will still be considered evaluable if the criteria above are not met 
and bleeding data can be impu ted for days with missing data (see Section 5.15.2 for details).  
Three other analyses of bleeding data will be pe rformed as follows:  
1. Using cycles in which all active pills were taken as per the instructions in the protocol. In this 
analysis, evaluable cycles will be defined as per the PP analysis but cycles where  there was  at 
least 1 day between Day 1 and Day 24  where a n active  pill was not taken  will be excluded . 
2. Using cycles in which exactly 1 active pill was missed . In this a nalysis, evaluable cycles will be 
defined as per the ITT analysis but only cycles where there was exactly 1 missed active pill  between 
Day 1 and Day 24 are included . 
3. Using cycles in which at least 2 active pill s were missed . In this analysis, evaluable cyc les will be 
defined as per the ITT analysis but only cycles where there were at least 2 missed active pill s 
between Day 1 and Day 24 are included . 
In addition, an analysis by RP will be performed where there are 4 91-day RPs defined  as follows:  
ÔÇ∑ RP1 = Day 1  to Day 91  
ÔÇ∑ RP2 = Day 92 to Day 182  
ÔÇ∑ RP3 = Day 183 to Day 273  
ÔÇ∑ RP4 = Day 274 to Day 364  
where Day 1 is the first day of Cycle 1 reported in the subject diary and then the remaining days are fixed 
using Day 1 as a reference. For example, Day 91 is 90 days afte r the date of the first day of Cycle 1.  
A RP will be considered to be non -evaluable in the ITT analysis when the RP is less than 91 days in duration 
(i.e. where the subject withdraws from the study during the RP). If there are any gaps between cycles in 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 11 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
terms of date within the RP  (i.e. at the end of the 4 -day inactive pill  period of a given cycle, the subject does 
not directly restart with the first active pill of the next pill pack) , then the RP will be excluded from the ITT 
Population. For example, if Cy cle 1 Day 28 is 1 February 2018 and Cycle 2 Day 1 is 3 February, then RP1 
will be excluded from the ITT.   
A RP with missing bleeding diary data will still be considered evaluable if the criteri a above are not met and 
bleeding data can be imputed for days w ith missing data (see Section 5.15.2  for details).   
5.2 Baseline  and Change from Baseline  
The B aseline  value for each assessment is defined as the last measurement taken prior to first 
administration  of study medication , unless oth erwise stated . When the date of the assessment is on the 
date of first administration, it will be assumed that the assessment was performed prior to first dose.  The 
Baseline value for the Menstrual Distress Questionnaire will be the value collected at Visi t 3 because the 
date of completion is not collected  in eCRF  for this questionnaire.  
For any parameter at a specific visit, change from Baseline is calculated as the value of that parameter at 
that visit minus the Baseline value of that parameter, as define d above.  
5.3 On-Treatment Period  
For contraceptive efficacy, t he On -Treatment Period is defined as the period of time between the date of 
first dose of study medication and 7 days after the last dose of study medication (regardless of whether this 
is an active  or inactive table), inclusive.  If the subject has a pregnancy after the first dose of study medication 
and prior to the last dose of study medication,  the On -Treatment Period is defined as the period of time 
between the date of first dose of study medicat ion and the date of the estimated date of conception , 
inclusive. If the subject has  a pregnancy when they are still on study medication but the estimated date of 
conception is missing because the date was not confirmed in an ultrasound, then the cycle and day of the 
estimated conception that is assigned from the narrative will be used to determine the end date.  
For TEAEs, the On -Treatment Period is defined as on or after  the date of first dose of study medication.  
For medications , the On -Treatment Period i s defined as the period of time between the date of first dose of 
study medication and the date of last dose of study medication (regardless of whether this is an active or 
inactive table), inclusive.  
If the subject had a period  of time when study medicat ion was not being taken between the date of first 
dose of study medication and the last dose of study medication, this time will still be considered to be during 
the On -Treatment Period.  
5.4 Body Mass Index  
BMI in kg/m2 will be calculated using the following f ormula:  
BMI=weight
height2 
Weight and height collected on the CRF will not be rounded prior to deriving BMI.  
5.5 Switchers, Starters and True New Users  
Starters are defined as subjects who have not used  hormonal contraceptives within the 3 months prior to 
the date of first dose of study medication.  
Switchers are defined as subjects who have used  hormonal contraceptives within the 3 months prior to the 
date of first dose of study medication.  
True new users are defined as subjects who have never received a  hormonal contraceptive. This group of 
subjects is a subset of the group of subjects classed as starters.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 12 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
5.6 Prior , Post -Study Treatment  and Concomitant Medication Use  
Medications will be categorised as contraceptives and other medications that are not contra ceptives.  
For contraceptives, the medications will be classed as prior if :  
ÔÇ∑ The question ‚ÄúTaken prior to study?‚Äù on the eCRF is answered with Y  or 
ÔÇ∑ The medication start date is before the date of first dose of study medication   
The following contraceptive medications will be identified as concomitant  contraceptives : 
ÔÇ∑ Medications with a start date during the On -Treatment Period  for medications  (see Section 5.3 for 
details)  
ÔÇ∑ Medications with a start date prior to the date of first d ose of study medication and an end date 
after the date of first dose of study medication  
Any contraceptive s with a missing end date will be considered to be ongoing at the end of study treatment 
and thus would be assumed to be after the first dose of study  medication and therefore assigned as a 
concomitant contraceptive .  
Contraceptive medications can be classed as both prior and concomitant.  
Contraceptive s with a start date occurring after the end of the On -Treatment Period  for medications  will be 
identifi ed as post -study treatment contraceptive s. Contraceptives with a start date prior to the date of first 
dose of study medication and an end date on the same date as the date of first dose of study medication 
will be assumed to be prior only and not concomit ant.  
For other medications that are not contraceptives, m edications with an end date occurring before the date 
of first dose of study medication will be identified as prior medications.  
Medication s with a start date occurring after the end of the  On-Treatment Period  for medications  will be 
identified as post -study treatment medications.  
The following m edications  will be identified as concomitant medications:  
ÔÇ∑ Medications  with a start date during the  On-Treatment Period for medications (see Section 5.3 for 
details)   
ÔÇ∑ Medications with a start date prior to the date of first dose of study medication  and an end date on 
or after the date of first dose of study medication   
Any medications with a missing end date will be considered to b e ongoing at the end of study treatment 
and thus would be assumed to be after the first dose of study medication  and therefore assigned as a  
concomitant  medication .  
Medications  that are not contraceptives  cannot be classed as both prior and concomitant.  
5.7 Study Treatment Compliance  
Treatment compliance for the investigational product will be assessed based on the data collected in the 
subject diary .  
5.7.1  Compliance analysis by cycle  
In the compliance analysis by cycle , a cycle will only be included if there is  a reported start date for that 
cycle. Prior to calculating any compliance data by cycle, cycles are first determined using the start date of 
the cycle and the start date of the next cycle, per the rules in Section 5.1. In the compliance analysis by 
cycle , only days within the cycle after those rules have been applied are included in the derivation of the 
endpoints in this Section by cycle.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 13 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
The treatment compliance will be calculated as a percentage and derived for each cycle th at the subject 
started . For each cycle, the total number of  pills (active or inactive) taken will be determined  from the subject 
diary . If an entry of the number of active  (pink)  or inactive  (white)  pills is left blank in the diary, then it will 
be assumed  that no pills were taken  on that day . 
The compliance for a given cycle will be derived as  
100  ùë• ùë°‚Ñéùëí ùë°ùëúùë°ùëéùëô  ùëõùë¢ùëöùëèùëíùëü  ùëùùëñùëôùëôùë†  ùë°ùëéùëòùëíùëõ  ùëëùë¢ùëüùëñùëõùëî  ùë°‚Ñéùëí ùëêùë¶ùëêùëôùëí
ùë°‚Ñéùëí ùëõùë¢ùëöùëèùëíùëü  ùëúùëì ùëùùëñùëôùëôùë†  ùëíùë•ùëùùëíùëêùë°ùëíùëë  ùë°ùëú ùëèùëí ùë°ùëéùëòùëíùëõ  ùëëùë¢ùëüùëñùëõùëî  ùë°‚Ñéùëí ùëêùë¶ùëêùëôùëí 
 
The number of pills expected to be taken during the cycle is derived as the end date of the cycle ‚Äì start 
date of the cycle + 1 where the start and end dates of the cycles are determined using the rules in Section 
5.1. In the case of  early termination from the study, in  the last cycle for that subject, the number of pills 
expected to be taken during  the cycle is calculated as the date of last dose of study medication ‚Äì the start 
date of the cycle o f interest + 1.   
In addition, the subject diary data will be used to identify when a pill has been missed. The number of 
missed pills will be derived for each cycle. In this situation, a pill is assumed to be missed if there is a day 
in the diary without a n entry for the number of tablets or with 0  active and 0 inactive  pills reported as taken . 
Any gaps between Day 28 of a cycle and Day 1 of the next cycle will be included as missed pills. For 
example, if the reported start date for Cycle 1 is 1 February an d the reported start date for Cycle 2 is 3 
March, then the derived end date of Cycle 1 will be  2 March  and 1 -2 March will be included as 2 missed 
pills. If there are overlapping cycles in terms of dates, then the days will be included under the latest cycl e 
and missed pills will be reported accordingly. For example, if the subject takes pills up to Day 24 in Cycle 
1, then starts Cycle 2 on the same date as Day 25 of Cycle 1, so Days 25 to Day 28 of Cycle 1 will not be 
included in Cycle1 and these will not b e counted as missed pills for Cycle 1.  
5.7.2  Overall compliance  
In the derivation of overall compliance, all data collected on days between the date of first dose and date 
of last dose will be included in the derivation. The overall compliance will be determine d by summing  the 
total number of  pills (active or inactive) taken across all cycles. The overall compliance will be calculated 
as 
100  ùë• ùë°‚Ñéùëí ùë°ùëúùë°ùëéùëô  ùëõùë¢ùëöùëèùëíùëü  ùëúùëì ùëùùëñùëôùëôùë†  ùë°ùëéùëòùëíùëõ  ùëéùëêùëüùëúùë†ùë†  ùëéùëôùëô ùëêùë¶ùëêùëôùëíùë†
ùë°‚Ñéùëí ùëëùëéùë°ùëí  ùëúùëì ùëôùëéùë†ùë°  ùëëùëúùë†ùëí ‚àíùë°‚Ñéùëí ùë†ùë°ùëéùëüùë°  ùëëùëéùë°ùëí  ùëúùëì ùëêùë¶ùëêùëôùëí  1+1 ùëñùëõ ùëëùëéùë¶ùë†   
In the above formula, the total number of pills taken during the cycle s will be the sum of pills recorded 
across  all days between the date of first dose of study medication and the dat e of last dose of study 
medication, inclusive. For example, if there is no start date reported for Cycle 1 and there are pills reported 
as taken in the diary for Cycle 1, then these pills reported in Cycle 1 will not be included in the total number 
of pill s taken as the date of first dose of study medication will be the start date reported for Cycle 2.  
The total number of pills taken across all subjects will be derived by summing the number of pills taken 
across the study for all subjects in the Safety Popu lation.  
For drug accountability , the number of active pills dispensed will be calculated by multiplying the number 
of blisters dispensed by 24. The  number of inactive pills dispensed will be calculated by multiplying the 
number of blisters dispensed by 4.  The number of active and inactive pills returned will be recorded  on the 
CRF. 
5.8 Extent of Exposure  
The duration  of total exposure to the investigational product in days will be determined from the first and 
last dosing dates during the treatment period and i s derived as the last dose date ‚Äì the first dose date + 1.  
The last dose date will be the date the last tablet was taken regardless of whether this is an active or inactive 
tablet.  The total extent of exposure across all subjects  in years  will be derived b y summing the total 
exposure in days across all subjects in the Safety Population  and dividing it by 365.25 to convert the units 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 14 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
from days to years . This will be used in the derivation of event rates for adverse events as this represents 
the duration of th e on-treatment period for treatment emergent adverse events.  
The duration of actual exposure to the investigational product in days will be determined by subtracting the 
total number of days where no pills were taken  from the duration of total exposure.  The total number of 
days where no pills were taken is equivalent to the total number of missed pills from Section 5.7 summed 
across all cycles for that subject. Days where no pills were taken include days between Day 28 of a cycl e 
and Day 1 of the next cycle where there are gaps between cycles and days within a cycle where there are 
no active or inactive pills taken . The total extent of actual exposure across all subjects in years will be 
derived by summing the exposure in days across all subjects in the Safety Population and dividing it by 
365.25 to convert the units from days to years.  
The duration of actual exposure will be used to determine whether or not a subject has had at least 26 
weeks exposure and whether or not a subject  has had at least 52 weeks exposure.  
The number of cycles of treatment will be derived for each subject by determining the number of cycles as 
per the definition provided in Section 5.1.  
5.9 Pregnancy Related Definitions  
The date of conception will be estimated for each reported pregnancy  by the Principal investigator . This 
estimated date of conception will be used to determine whether the pregnancy was pre -, on- or post -
treatment. In addition, the estimated date of conception will  be reviewed alongside the compliance data 
recorded on the subject diary  and the pregnancy narrative completed by the PI  to determine whether the 
pregnancy  occurred in a compliant (Product Failure) or non -compliant (User -Failure) subject with 
compliance su ggesting method  failure and non -compliance suggesting  user failure. The definitions of pre -
, on- and post -treatment pregnancies and for method and user failure pregnancies are provided below.  
5.9.1  Pre-Treatment Pregnancies  
Pre-treatment pregnancies are pregnanc ies with an estimated date of conception before the date of the 
first dose of study medication.  
5.9.2  On-Treatment Pregnancies  
On-treatment pregnancies are pregnancies with an estimated date of conception during the On-Treatment 
Period  for contraceptive efficacy  (see Section 5.3 for the definition of the On -Treatment Period) . In cases 
where the date of conception cannot be established unequivocally (e.g. subjects is lost to follow up), this 
pregnancy will be considered as on -treatment  pregnancy.   
For on -treatment pregnancies, the cycle and day  within the cycle  of conception will be assigned based on 
the diary data collected and the estimated conception date. If the on -treatment pregnancy has an estimated 
date of conception in the 7 -days after the last dose of study medication, then the cycle of conception will 
be the cycle in which the last dose of study medication was taken and the day of conception will be not 
applicable.  
5.9.3  Post -Treatment Pregnancies  
Post-treatment pregnancies are pregn ancies with an estimated date of conception after the end of the  On-
Treatment Period  for contraceptive efficacy . 
5.9.4  Method and User Failure Pregnancies  
User failure pregnancies are pregnancies where the subject did not take the study medication correctly as 
per Section 9.4.4 of the Protocol during the cycle in which the estimated  date of  conception occurred  or 
used drugs  that have the  potential  to trigger interactions with COC  (Section 9.4.6 of the Protocol) . 
Pregnancies not identified as due to user failure will be considered to be method failure pregnancies.  The 
pregnancy narratives from the P rincipal Investigator  are used to determine whether a pregnancy is a user 
or method failure pregnancy.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 15 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
Each on -treatment pregnancy will be reviewed  in conjunction with the data collected  and classified as either 
a method failure or a user failure pregnancy prior to database lock.  
5.10 Bleeding Patterns  
The subject diary data will be used to characterize bleeding patterns.  Bleeding data will be analyzed by 
cycle and by RP . 
5.10.1  Definitions of Bleeding and Spotting  
Definitions for bleeding and spotting used for the cycle and RP analysis are provided in Table 1 below . In 
the diary, ‚Äú0‚Äù was to be ticked  for no bleeding or spotting, ‚Äú1‚Äù for spo tting and ‚Äú2‚Äù for bleeding.  
Table 1: Bleeding and spotting definitions  
Term  Definition  
Bleeding  Evidence of vaginal blood loss that requires the use of sanitary protection with a 
tampon, pad or pantyliner . 
Spotting  Evidence of min imal vaginal  blood loss that does not require new use of sanitary 
protection, including pantyliners . 
Bleeding day  Day where bleeding  (2) was reported for that day in the subject diary  
Spotting da y Day where spotting (1) was reported for that day in the s ubject diary  
Bleeding/spotting -
free day Day where no bleeding or spotting (0) was reported in the subject diary  
 
Bleeding/Spotting  
episode  One or more consecutive b leeding  and/or spotting days  where there are both 
bleeding and spotting days  bounded on ei ther end by 2 bleeding/spotting -free 
days  
Bleeding only 
episode  One or more consecutive bleeding days  where there are no spotting days  bounded 
on either end by 2 bleeding /spotting -free days  
Spotting only 
episode  One or more consecutive spotting days  wher e there are no bleeding days  bounded 
on either end by 2 bleeding/ spotting -free days  
Bleeding/spotting -
free episode  Two or more consecutive bleeding/spotting -free days bounded on either end by a 
bleeding  or spotting day  
 
5.10.2  Cycle analysis  
5.10.2.1  Definition of cycle s 
In the  cycle analysis of a 24/4 regimen of a COC, an up to 7 -day vaginal bleeding is scheduled to occur in 
conjunction with the first inactive tablet  (Day 25) and end on Day 3 of the next cycle  (expected bleeding 
period) . In principle, no vaginal bleedin g is expected to occur at other times during the cycle. This means 
that the remainder of the cycle constituted the expected non -bleeding period of 21 days. Therefore, any 
bleeding/spotting that occur s during the expected non -bleeding period (starting on Da y 4 of the actual cycle 
up to and including Day 24 ) are considered as unscheduled.  
The following definitions ( Table 2) will be used for the cycle analysis:  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 16 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
Table 2: Bleeding/spotting definit ions used for the cycle analysi s 
Scheduled 
Bleeding/Spotting 
(Withdrawal 
Bleeding /Spotting ) Any bleeding/spotting that occurs during the hormone -free interval (i.e. Days 25 
‚Äì 28) and continues through Days 1 -3 of the subsequent active cycle.  
Note: any blee ding/spotting that occurs while taking active hormones during 
Days 1 -7 of the first cycle will be imputed as no bleeding.  
Unscheduled 
Bleeding/Spotting  Any bleeding /spotting  that occurs while taking active hormones  that does not 
meet the criteria for sche duled bleeding/spotting . 
Unscheduled 
Bleeding  Any bleeding that occurs while taking active hormones that does not meet the 
criteria for scheduled bleeding . 
Unscheduled 
Spotting  Any spotting that occurs while taking active hormones that does not meet the 
criteria scheduled spotting . 
Early Withdrawal 
Bleeding/Spotting  Any bleeding/spotting episode that starts before the scheduled bleeding/spotting 
period and continues into the scheduled bleeding/spotting period . 
Continued 
withdrawal 
bleeding /spotting  Any bleeding/spotting episode that starts in the scheduled bleeding/spotting 
period and continues after the scheduled bleeding/spotting period . 
 
  
Based on th ese definition s, the cycle analysis of bleeding/spotting episodes will perform in two ways:  
ÔÇ∑ a classic al approach  
ÔÇ∑ a modified cycle analysi s  
5.10.2.2  Classical cycle analysis  
In the classical analysis,  early and continued withdrawal bleeding are regarded  as scheduled.  
The following  rules will be used for the classical approach  to classify each bleeding only episode , spotting 
only episode or bleeding/ spotting episode  as scheduled or unscheduled : 
The episode is defined as unscheduled , if any of the following criteria are met:  
ÔÇ∑ The episode has a start date after Day 7 of Cycle 1 and an end date that is on or before Day  24 of 
Cycle 1  
ÔÇ∑ For Cycles 2 to 13, the episode has a start date after Day 3 of the cycle and an end date that is on 
or before Day 24 of the cycle  
The episode is defined as scheduled  (withdrawal bleeding and/or spotting), if any of the following criteri a 
are met: 
ÔÇ∑ The episode has a start date after Day 24 of the cycle and an end date that is on or before Day 3 
of the next cycle  
ÔÇ∑ The episode has a start date after Day 24 of the cycle and an end date that is  after Day 3 of the 
next cycle  (continued withdrawal bl eeding/spotting) .  
o Note it is not possible to have continued withdrawal bleeding for Cycle 13 because data 
are not collected for Cycle 14  
ÔÇ∑ The episode has a start date before Day 24 of the cycle and an end date on or after Day 25 (early 
withdrawal bleeding/ spotting) . 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 17 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
All bleeding days  and spotting days  will then be classified as scheduled or unscheduled  based on whether 
the bleeding or spotting days are included in a scheduled or unscheduled episode  using the rules in this 
Section above . A bleeding day  or spotting day that occurs in a scheduled episode  will be classified as 
scheduled  and a bleeding day or spotting day that occurs in an unscheduled epis ode will be classified as 
unscheduled .  
5.10.2.3  Modified Cycle Analysis  
In the modified cycle analysis, the definiti ons of expected non -bleeding and expected bleeding periods  are 
strictly followed, i.e., all bleeding episodes that overlap with expected non -bleeding intervals are considered 
unscheduled. Thus in this analysis , the definitions of scheduled and unscheduled bleeding/spotting 
episodes presented in the Table 2 are also applicable , but early and continued withdrawal bleedings are 
regarded as unscheduled.  
Therefore,  in the derivation of endpoints where early and continued withdrawal bleeding are classed as 
unsche duled  bleeding the following rules are used  to classify each bleeding only episode, spotting only 
episode or bleeding/ spotting episode  as scheduled or unscheduled :  
The episode is defined as unscheduled , if any of the following criteria are met:  
ÔÇ∑ The episo de has a start date after Day 7 of Cycle 1 and an end date that is on or before Day 24 of 
Cycle 1  
ÔÇ∑ For Cycles 2 to 13, the episode has a start date after Day 3 of the cycle and an end date that is on 
or before Day 24 of the cycle  
ÔÇ∑ The episode has a start dat e after Day 24 of the cycle and an end date that is  after Day 3 of the 
next cycle  (continued withdrawal bleeding/spotting)   
o Note it is not possible to have continued withdrawal bleeding for Cycle 13 because data 
are not collected for Cycle 14  
ÔÇ∑ The episode h as a start date before Day 24 of the cycle and an end date that is on or after Day 25 
(early withdrawal bleeding/spotting)  
The episode is defined as scheduled  (withdrawal bleeding and/or spotting), if the following criterion is met:  
ÔÇ∑ The episode has a start  date after Day 24 of the cycle and an end date that is on or before Day 3 
of the next cycle  
All bleeding days  and spotting days  will then be classified as scheduled or unscheduled  based on whether 
the bleeding or spotting days are included in a scheduled or unscheduled episode in the same way as 
outlined for the classical analysis but using the rules in this Section above  where early and continued 
withdrawal bleeding are classed as unscheduled episodes .  
5.10.3  Reference Periods (RPs)  
No additional definitions  other than those displayed in Table 1  were used for the reference period analysis.   
5.10.4  Bleeding Endpoints for the Cycle Analysis  
For the cycle analysis, the evaluable cycles will be determined as described in Section 5.1 for each subject, 
missing data rules are provided in Section 5.15.2  and definitions of terminology are provided in Section 
5.10.1  and 5.10.2 .  
Depending on the a pproach used for the cycle analysis (the classical approach versus the modified cycle 
analysis), f or each evaluable cycle for each subject, the following  will be determined : 
ÔÇ∑ Whether there was at least one unscheduled bleeding only,  spotting  only or bleedin g/spotting  
episode within that cycle  (see Section 5.10.2  for definition) . It will be assumed that there is at least 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 18 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
one unscheduled episode during the cycle  if there is an unscheduled episode that starts in  the cycle 
of interes t 
ÔÇ∑ Whether there was at least one unscheduled bleeding only episode within that cycle (see Section 
5.10.2  for definition)  and no unscheduled bleeding/spotting episodes and no unscheduled spotting 
only episodes . It will be assume d that there is at least one unscheduled  bleeding only  episode 
during the cycle if there is an unscheduled bleeding only  episode that starts in the cycle of interest  
ÔÇ∑ Whether there was at least one unscheduled spotting  only episode within that cycle (see Se ction 
5.10.2  for definition)  and no unscheduled bleeding/spotting episodes and no unscheduled bleeding 
only episodes . It will be assumed that there is at least one unscheduled  spotting  only episode during 
the cycle if there is an unscheduled  spotting  only episode that starts in the cycle of interest  
ÔÇ∑ Whether there is an absence of any bleeding or spotting (i.e. all days in the cycle are 
bleeding/spotting -free days)  
ÔÇ∑ Whether there is an absence of scheduled bleeding only, spotting  only and bleeding/spotting  
episode s (i.e. there is no scheduled episode with a start date during that cycle of interest )  
ÔÇ∑ Whether there is early withdrawal bleeding  or spotting  in that cycle (i.e. there is  either an  early 
withdrawal  bleeding only, spottin g only or bleeding/spotting episode  that starts during the cycle of 
interest)  
ÔÇ∑ Whether there is continued withdrawal bleeding  or spotting  in that cycle (i.e. there is either a 
continued withdrawal bleeding only, spotting only or bleeding/spotting episode  that starts during 
the cycle of interest)   
ÔÇ∑ The total (scheduled + unscheduled) number of days with bleeding and/or spotting  (i.e. the number 
of bleeding days + the number of spotting days  within the bleeding only, spotting only and 
bleeding/spotting episodes  that start during the cycle of interest ) 
ÔÇ∑ The total (scheduled + unscheduled) number of days with bleeding only (i.e. the number of bleeding 
days within the bleeding only and bleeding/spotting episodes that start during the cycle of interest)  
ÔÇ∑ The total (sc heduled + unscheduled) number of days with spotting only (i.e. the number of spotting 
days within the spotting only and bleeding/spotting episodes that start during the cycle of interest)  
ÔÇ∑ The number of unscheduled days with bleeding and/or spotting (i.e. t he number of bleeding days 
+ the number of spotting days  within the unscheduled bleeding only, spotting only and 
bleeding/spotting episodes that start during the cycle of interest )  
ÔÇ∑ The number of unscheduled days with bleeding only (i.e. the number of blee ding days within the 
unscheduled bleeding only and bleeding/spotting episodes that start during the cycle of interest)  
ÔÇ∑ The number of unscheduled days with spotting only  (i.e. the number of spotting days within the 
unscheduled spotting only and bleeding/spo tting episodes that start during the cycle of interest)   
ÔÇ∑ The number of scheduled days with bleeding and/or spotting (i.e. the number of bleeding days + 
the number of spotting days  within the scheduled bleeding only, spotting only and bleeding/spotting 
episodes that start during the cycle of interest )  
ÔÇ∑ The number of scheduled days with bleeding only  (i.e. the number of bleeding days within the 
scheduled bleeding only and bleeding/spotting episodes that start during the cycle of interest)  
ÔÇ∑ The number of schedu led days with spotting only (i.e. the number of spotting days within the 
scheduled spotting only and bleeding/spotting episodes that start during the cycle of interest)  
ÔÇ∑ The start da y for any scheduled bleeding episodes that have a start date within the cyc le (if there 
are more than one scheduled bleeding episodes in the cycle, then only the start day of the earliest  
episode  will be used )  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 19 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
5.10.5  Bleeding Endpoints for Analyses by RP  
For the analyses by  RP, the evaluable RPs  will be determined as described in Secti on 5.1.2  for each 
subject , missing data rules are provided in Section 5.15.2  and definitions of terminology are provided in 
Section  5.10.1 .  
The following variables will be derived for each  evaluable  RP and subject:  
ÔÇ∑ The total number of days with bleeding and/or spotting  (i.e. the number of bleeding days + the 
number of spotting days within the bleeding only, spotting only and bleeding/spott ing episodes 
that start during the RP of interest)   
ÔÇ∑ The total number of days with bleeding only (i.e. the number of bleeding days within the 
bleeding only and bleeding/spotting episodes that start during the RP of interest)  
ÔÇ∑ The total number of days with sp otting only (i.e. the number of spotting days within the spotting 
only and bleeding/spotting episodes that start during the RP of interest)  
ÔÇ∑ The number of bleeding and/or spotting episodes  
ÔÇ∑ The mean duration of the bleeding and/or spotting  episodes  
ÔÇ∑ The numbe r of bleeding and/or spotting free episodes  
ÔÇ∑ The mean duration of the bleeding and/or spotting free episodes  
For the number of bleeding and/or spotting episodes in the RP, the number of episodes is defined as the 
number of bleeding only episodes  + the num ber of spotting only episodes + the number of spotting/bleeding 
episodes  with a start date during that RP. The duration of an episode is derived as the end date of the 
episode ‚Äì start date of the episode + 1. The mean duration of episodes in the RP is deri ved from the 
duration of all episodes with a start date during that RP. The full duration of each of the episodes is used in 
the derivation of the mean duration, even if the episode continues beyond the end of the RP.  
5.11 Treatment -Emergent Adverse Event (TEAE ) 
A TEAE is defined as an AE with a start date  or worsening  during the On -Treatment Period for TEAEs (see 
Section 5.3 for definition of the On -Treatment Period) . 
If the start date for an AE is missing and the end date is either  missing or on or after the date of first dose 
of study medication, then the AE will be assumed to be treatment -emergent. However, if the start date for 
an AE is missing and the end date is recorded and is before the first dose of study medication, then th e AE 
will be assumed to be non -treatment emergent.  
5.12 Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q -
LES-Q-SF) 
The total score of the Q -LES-Q-SF (see Appendix 4 of the Protocol) will be derived by summing the first 14 
items to obtain t he raw total score. The raw total score is then transformed into a percentage maximum 
using the following formula:  
ùëÉùëíùëüùëêùëíùëõùë°ùëéùëîùëí  ùëÄùëéùë•ùëñùëöùë¢ùëö =(ùëüùëéùë§  ùë°ùëúùë°ùëéùëô  ùë†ùëêùëúùëüùëí  ‚Äì 14)
56 
In the case of questions with missing results, if  10 or more que stions are answered, then  the percentage 
maximum is derived as follows:  
  
ùëÉùëíùëüùëêùëíùëõùë°ùëéùëîùëí  ùëÄùëéùë•ùëñùëöùë¢ùëö =(ùëüùëéùë§  ùë°ùëúùë°ùëéùëô  ùë†ùëêùëúùëüùëí  ùëìùëúùëü ùë°‚Ñéùëí ùëûùë¢ùëíùë†ùë°ùëñùëúùëõùë†  ùëéùëõùë†ùë§ùëíùëü  ‚Äì ùëõùë¢ùëöùëèùëíùëü  ùëúùëì ùëûùë¢ùëíùë†ùë°ùëñùëúùëõùë†  ùëéùëõùë†ùë§ùëíùëü )
(ùë°‚Ñéùëí ùëõùë¢ùëöùëèùëí ùëü ùëúùëì ùëûùë¢ùëíùë†ùë°ùëñùëúùëõùë†  ùëéùëõùë†ùë§ùëíùëüùëíùëë  √ó 4) 
If fewer than 10 questions are answered, then the percentage maximum will be considered to be missing.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 20 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
The change from Baseline at the end  of treatment will be calculated for each subject.  
5.13 Menstrual Distres s Questionnaire   
The Menstrual Distress Questionnaire  (see Appendix 5 of the Protocol)  will be scored according to the 
manual  (Moos, 1968 ). The following scales will be derived by summing the items that fall within that 
speci fied category: pain, water retention, autonomic reactions, negative affect, impaired concentration, 
behavior change, arousal and control. Each of these are derived at each visit for the menstrual (most recent 
flow in CRF), premenstrual (4 days before in th e CRF) and intermenstrual (remainder of the cycle in the 
CRF) phases by summing the items that fall under the specified scale. The scoring key is presented in 
Table 3 below.  If the subject does not answer one item on any of the scale, then the scale is calculated by 
deriving the mean score for the answered items and adding that number to the sum of the answered items 
within that scale. If 2 or more items within a scale are not answered, then the scale is missing. The change 
from Baseline at the end of treatment will be calculated for each subject.  
Table 3: Menstrual Distress Questionnaire Scoring Key  
Scale  Items  
Pain 1, 2, 3, 4, 5, 6  
Water Retention  7, 8, 9, 10  
Autonomic Reactions  11, 12, 1 3, 14  
Negative Affect  15, 16, 17, 18, 19, 20, 21, 22  
Impaired Concentration  23, 24, 25, 26, 27, 28, 29, 30  
Behaviour Change  31, 32, 33, 34, 35  
Arousal  36, 37, 38, 39, 40  
Control  41, 42, 43, 44, 45, 46  
 
5.14 Return to Fertility  
Each woman who discontinues the study due to a pregnancy wish will be followed -up after study treatment 
discontinuation to evaluate return of spontaneous menstruation , return of fertility , or initiation of hormonal 
contraception, whichever comes first .  
The date of the first spontane ous menstruation after study discontinuation will be recorded in the eCRF and 
follow -up will be continued. Once a pregnancy is reported or once a new contraceptive method has been 
started, the date of expected pregnancy term or of contraceptive treatment i nitiation will be recorded in the 
eCRF and no further follow -up contact will be done. The time from last dose of study medication to the 
return to menstruation will be calculated as the date of return of menses ‚Äì the date of last dose of study 
medication.  If the subject‚Äôs fertility information indicates that she had confirmation of pregnancy, then time 
from last dose of study medication to the estimated date of conception  will be calculated as the estimated 
date of conception  ‚Äì the date of last dose of stud y medication.  The estimated date of conception will be 
derived as the date of expected pregnancy term ‚Äì 38 weeks  (266 days) . If the subject‚Äôs fertility information 
indicates that she received a new contraceptive method, then time from last dose of study me dication to 
the date of the new contraceptive method will be calculated as the date of new contraceptive method ‚Äì the 
date of last dose of study medication.  
5.15 Methods for Handling Missing Data  
5.15.1  Missing Data Related to the Pearl Index and Pill Intake  
In the de rivation of the Pearl Index, i f the subject did not respond to the question on other contraceptive 
methods in the subject diary, it will be assumed that another contraceptive method was used . The  cycle will 
be classed as a not at-risk cycle and excluded fr om the denominator of the Pearl Index. If the subject did 
not respond to the question on sexual intercourse in the subject diary, it will be assumed that she did not 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 21 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
have sexual intercourse and that cycle will be classed as a not at-risk cycle and excluded  from the 
denominator of the Pearl Index  as appropriate . 
For compliance, i f the number of active (pink) and inactive (white) pills is blank in the diary, then it will be 
assumed that no pills were taken on that day.  
If there is a partial start date for a c ycle, then the start date will be imputed as the day after the date of Day 
28 of the previous cycle, providing the imputed date is consistent with the non -missing part of the date 
reported and that the duration of the cycle is consequently consistent with the expected 28 days.  For rules 
around missing or partial start dates for Cycle 1, see Section 5.15.5 . 
5.15.2  Missing Bleeding  Data  
One or two consecutive days with missing bleeding information will be interpolated with the bleeding 
information from the previous day. For three or more consecutive days with missing bleeding information, 
missing data will be interpolated using the worst bleeding observation of the bordering days. If there are 3 
or more consecutive days with missing bleed ing information at the end of the diary with no non -missing 
data reported afterwards, then the missing bleeding information will be interpolated with the bleeding 
information from the day immediately prior to the missing days. Data missing after withdrawal  from the 
study will not be imputed.   
In the case of an ambiguous response for bleeding on a given day, the worst response recorded will be 
used. For example, if both bleeding and spotting are reported, then the response will be set to bleeding. If 
both bl eeding and absence of vaginal bleeding or spotting are reported, then the response will be set to 
bleeding. If both spotting and absence of vaginal bleeding or spotting are reported, then the response will 
be set to spotting. If bleeding, spotting and abse nce of vaginal bleeding or spotting are reported, then the 
response will be set to bleeding.  
The first 7 days of Cycle 1 will be imputed with no bleeding. It will be assumed that the bleeding data for 
the 3 days after the end of Cycle 13 is the same as tha t of the last day of Cycle 13 where bleeding data 
were recorded .  
5.15.3  Missing  or Partial Dates for Medications   
In the determination of whether a medication is taken during the On -Treatment Period, the following rules 
for missing and partial dates will be appl ied:  
ÔÇ∑ If the end date is before the first dose of study medication, then the medication is a prior medication, 
regardless of whether or not the start date is missing or partially missing  
ÔÇ∑ If the end date is on or after the date of first dose of study medic ation, then the following rules will 
be applied for missing or partially missing start dates:  
o If the start date is completely missing, then the medication will be assumed to be 
concomitant.  
o If only the year of the start date is recorded and the year is eit her before or the same year 
as the end of the safety On -Treatment Period, then the medication will be assumed to be 
concomitant.  
o If only the year of the start date is recorded and the year is after the year of the end of the 
safety On -Treatment Period, it  will be considered to be a post -study treatment medication.  
o If only the year and the month of the start date is recorded and the month specified is either 
before or the same month as the end of the safety On -Treatment Period, then the 
medication will be assumed to be concomitant  
o If only the year and the month of the start date is recorded and the month specified is after 
the month of the end of the safety On -Treatment Period, it will be considered to be a post -
study treatment medication.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 22 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
Rules for dealing  with missing start and stop dates for study medication for the classification of medications 
are in Section 5.15.5 . 
5.15.4  Missing or Partial Dates for AEs   
If the start date for an AE is missing and the end date is either missing or  on or after the date of first dose 
of study medication, then the AE will be assumed to be treatment -emergent. However, if the start date for 
an AE is missing and the end date is recorded and is before the first dose of study medication, then the AE 
will b e assumed to be non -treatment emergent.  
Rules for dealing with missing start and stop dates for study medication for the classification of AEs are in 
Section 5.15.5 . 
5.15.5  Missing  or Partial  Treatment Start and Stop Dates  
5.15.5.1  Missing Tre atment Start and Stop Dates  
If the subject has no diary data but has a pregnancy as per P rincipal Investigator‚Äôs  assessment in the 
pregnancy narrative that is classified as on -treatment or post treatment, then the subject will be classed as 
treated. The treatment start date and treatment stop date would be unknown in this situation.  
In the case of post -treatment pregnancies, the cycle for censoring for the cumulative event rates for 
pregnancies  cannot be determined and this will be missing. The subject wil l also consequently have no 
evaluable cycles for the Pearl Index. In the case of on-treatment pregnancies, the cycle of conception from 
the narrative will be used in the derivation of the cumulative event rates for pregnancies and in the derivation 
of the Pearl Index but for the Pearl Index no other cycles would be included in the denominator for that 
subject.  
When classifying concomitant , pre - and post medication and treatment emergent AEs  and defining the 
Baseline assessments , the treatment start date wi ll be assumed to be the first date in which the 
investigational product was dispensed and the treatment end date will be assumed to be the discontinuation 
or completion date for that subject. However, the start and stop dates for study medication will  rema in 
missing and  the compliance  and exposure will not be calculated. Similarly, the cycle of discontinuation of 
study medication cannot be determined and therefore this would remain missing for such subjects. The 
subject will have no evaluable cycles for the  bleeding analysis.  
5.15.5.2  Partial Treatment Start Dates  
If the subject has a partial start date Cycle 1 , and consequently a partial start date for study medication, 
then the partial start date will be presented in the listing. If the date of last dose cannot be  derived as a 
result of the partial start date, then this will be blank in the listings as the end date is unknown.   
In the case of an on -treatment pregnancy, the cycle of conception will be estimated from the available data. 
If the subject does not have a n on-treatment pregnancy, then for the cumulative event rates for pregnancy, 
the subject will be censored in the cycle where the last pill intake was reported per the diary data. Cycle 1 
will be included in the denominator for the Pearl Index following the  rules in Section 5.1.1  and will be 
included in the bleeding analysis following the rules in Section 5.1.2 .  
In this case, when classifying concomitant, pre - and post medication and treatment emerge nt AEs and 
defining the Baseline assessments, the treatment start date will be assumed to be the first date in which 
the investigational product was dispensed. If the treatment end date cannot be determined as a result of 
the partial start date, then the d ate of last dose will be derived for the day in the diary where the last pill is 
reported and by assuming that the start date is the latest possible day. For example, if the partial start date 
is January 2017 and the last day with a pill reported is Day 4 of Cycle 1, then the assumed start date would 
be 31 January 2017 and therefore Day 4 of Cycle 1 would be 3 February  2017 and this would be used as 
the date of last dose.  The diary data for pill intake will be used to derive compliance and exposure per the 
rules in the SAP.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 23 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
6.0 Analysis Sets  
6.1 Screened Population  
The Screened Population includes all subjects who signed an  informed consent  (IC) form.  
The Screened Population will be used for disposition data and data will be displayed for subjects aged 1 6 
to 35 yea rs and for all subjects in separate columns.  
6.2 Enrolled Population  
The Enrolled Population includes all enrolled subjects  (i.e. subjects who had a non -missing enrollment date 
on the enroll ment page of the  CRF) . 
The Enrolled Population will be used for summar ies of enrollment per country.  
6.3 Safety  Population  
The Safety Population includes all enrolled subjects who receive at least one dose of study medication .  
If a subject returns all study medication that was dispensed, then the subject will not be included in  the 
Safety Population. If there is at least one pill that was dispensed but was not returned, but the subject diary 
has no pills recorded as taken, then it will be assumed that the subject has not taken any study medication 
and will not be included in the  Safety Population. However, if the subject has no pills taken according to the 
diary but the subject has a pregnancy that is classified as per P rincipal Investigator‚Äôs  assessment in the 
pregnancy narrative as either an on -treatment or post treatment pregn ancy, then the subject will be included 
in the Safety Population. In the case of missing diary data, it will be assumed that no pills were taken for 
the corresponding days with missing data. If there was at least one pill that was dispensed but was not 
returned and the subject has taken at least one pill according the subject diary, then that subject will be 
included in the Safety Population.   
The Safety Population will be used for compliance  and exposure  data with data displayed for subjects aged 
16 to 35 years and for all subjects in separate columns. The Safety Population will also be  used for safety 
presented for all subjects.  
Follow -up evaluations will be presented for subjects in the Safety Population who discontinued study 
medication with pregnancy wi sh as the reason for discontinuation.  
6.4 Intention -to-Treat (ITT) Population  
The ITT Population includes all enrolled subjects who receive at least one dose of study medication . The 
ITT Population is the same as the Safety Population for this study.  
The ITT P opulation will be used for baseline and contraceptive efficacy data with data displayed for 
subjects aged 16 to 35 years  and for all subjects in separate columns. The ITT Population will also be 
used for  protocol deviations,  bleeding and quality of life da ta with data presented for all subjects.   
6.5 Per-Protocol (PP) Population  
The bleeding data  cycle analysis  will be presented in the PP Population. For the bleeding analysis, the PP 
Population will exclude cycles based on the rules in Section 5.1.2 . Subjects  in the ITT Population  with at 
least one evaluable cycle for the bleeding analysis will be included in the PP Population and only their 
evaluable cycles will be included in the PP analysis for bleeding data.  Subjects will be excl uded from the 
PP Population  entirely  if they have no evaluable cycles for the bleeding analysis.  
6.6 Pharmacokinetics (PK) Population  
The PK Population includes all subjects enrolled in the PK Substudy who provide concentration data for at 
least one sample.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 24 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
The PK Population will be used for all PK analysis described in Section 9.8. 
7.0 Interim Analyses  
There are no planned interim analyses for this study.  
8.0 Data Review  
8.1 Data Handling and Transfer  
Processes for data handling and transfer w ill be documented in the  Data Management Plan.  
8.2 Data Screening  
Beyond the data screening built into the PRA Data Management Plan, the PRA programming of analysis 
datasets, tables, figures, and listings (TFL) provides additional data screening. Presumed data  issues will 
be output into SAS logs identified by the word ‚ÄúProblem‚Äù and extracted from the logs by a SAS macro and 
sent to Data Management.  
Review of a pre -freeze TFL run on clean subjects and a post -freeze TFL run on the frozen database allow 
for furthe r data screening prior to lock. The post -freeze TFL will be discussed with the sponsor in a data 
review meeting to identify any final data issues and seek corrections prior to database lock. The PRA 
statistician and the sponsor must approve database lock.  
8.3 Data Review Meetings  
Data review meetings will be held during the course of the study prior to database lock and the following 
may be reviewed during these meetings:  
ÔÇ∑ Important protocol deviations and exclusion from the PP Population  
ÔÇ∑ Classification of at-risk and not at-risk cycles for the Pearl Index derivation  where the classification 
is not clear based on the data collected and the rules in the SAP  
ÔÇ∑ Classification of on -, pre- and post - treatment pregnancies for the Pearl Index derivation  
ÔÇ∑ Classification of  method failure and user failure pregnancies for the method failure Pearl Index 
derivation  
ÔÇ∑ Classification of evaluable and non -evaluable cycles for the PP bleeding analysis where the 
classification is not clear based on the data collected and the rules in the SAP  
9.0 Statistical Methods  
All analyses will be conducted using SAS version 9.4 or higher.  
No formal statistical analyses will be performed  in this study . 
The following conventions will be used when presenting summary statistics for study data:  
ÔÇ∑ Continuous  variables will be summarized using the following descriptive statistics: number of 
subject s (n), mean, standard deviation (SD),  standard error of the mean (SEM),  median, minimum 
(min), maximum (max) , 25th percentile (lower quartile or Q1) and 75th percent ile (upper quartile or 
Q3) 
ÔÇ∑ Categorical and count variables will be summarized by the number of subjects (n) and the percent 
of subjects in each category.  For AE tables, m may also be presented which represents the number 
of events.  Percentages will be pres ented to 1 decimal place  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 25 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
ÔÇ∑ The number of subjects or observations will be presented as an integer  
ÔÇ∑ Mean , median , lower quartile and upper quartile  will be presented to 1 decimal place more than the 
raw value  
ÔÇ∑ Min and max will be presented to the same number of  decimal places as the raw value  
ÔÇ∑ Standard deviation will be presented to 2 decimal places more than the raw value, up to a 
reasonable number of decimal places (i.e., rarely more than 3 decimal places unless the nature of 
the data suggests this)  
ÔÇ∑ The denomin ator for percentage calculations will be the number of non -missing observations at 
that visit. Where this isn‚Äôt appropriate, the number of subjects in the relevant population will be used  
9.1 Subject Disposition  
All summaries in this Section will be presented for subjects aged 16 to 35 years  and for all subjects. This 
will be based on the Screened Population.  
The number and percentage of subjects  treated in the study will be presented, together with the number 
and percentage of subjects who  completed the study and the number and percentage of subjects who  
withdrew from the study prematurely with a breakdown of the corresponding reasons for withdrawal.  If a 
subject returns all study medication that was dispensed, then the subject will not be classed as treated. I f 
there is at least one pill that was dispensed but was not returned, but the subject diary has no pills recorded 
as taken, then it will be assumed that the subject has not taken any study medication and will not be classed 
as treated. However, if the subj ect has no pills taken according to the diary but the subject has a pregnancy 
that is classified as either an on -treatment or post treatment pregnancy based on the  Principal Investigator‚Äôs  
assessment in the pregnancy narrative , then the subject will be  classed as treated . In the case of missing 
diary data, it will be assumed that no pills were taken for the corresponding days with missing data. If there 
was at least one pill that was dispensed but was not returned and the subject has taken at least one pill  
according the subject diary, then that subject will be classed as treated.   
Tabulations of the number and percentage of subjects included in each analysis set will be provided.  The 
percentage will not be presented for the Screened and Enrolled Populations . Percentages will be derived 
based on the number of subjects enrolled.  
A tabulation of the number and percentage of subjects  enrolled at each site and country  will be summariz ed 
in the Enrolled Population . 
Disposition data and the site and country will be  listed  in the Enrolled Population . Information on inclusion 
in each of the analysis sets will be listed in the Screened Population.  Screening failures will be listed with 
the reason for the screening failure.  
The cumulative discontinuation rate, as determ ined by life -table methods, together with the corresponding 
95% CIs will be presented in the ITT population for all subjects and for subject‚Äôs aged 16 to 35 years  
inclusive at Screening. The life -table analysis will evaluate the cumulative probability of d iscontinuation from 
the study by cycle using PROC LIFETEST in SAS where the time variable is the cycle where the 
discontinuation occurred for subjects who discontinued from the study prematurely. Subjects who did not 
discontinue from the study prematurely will be censored in Cycle 13. The rate of discontinuation and 95% 
CIs will be calculated based on Kaplan -Meier estimates for each cycle. Additionally, the estimated survival 
function against time (cycle) will be provided.   
9.2 Protocol Deviations and Violation s 
The important protocol deviations for this study will be specified in the Protocol Deviation Guidance 
Template. Per PRA processes, protocol deviations will be entered into PRA‚Äôs Clinical Trials Management 
System (CTMS). The study team and the sponsor wil l conduct ongoing reviews of the protocol deviation s 
from CTMS to identify deviations which meet the criteria for important.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 26 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
The number and percentage of subjects who had an important protocol deviation will be summarized in the 
ITT Population . 
All import ant protocol deviations will be listed  in the ITT Population . 
The important protocol deviations will be reviewed and their potential to impact the analysis of the bleeding 
data will be assessed against the rules specified in Sections 5.1.2 . If there is a potential for a specific 
important protocol deviation to impact this analysis, then the impacted cycles for that subject will be 
excluded from the PP analysis for bleeding data. Subjects with no evaluable cycles will be excluded  from 
the PP Population for the analysis of bleeding data . The PP Population  and the cycles to be excluded from 
the PP analysis  must be finalized at the post -freeze data review meeting (or earlier), prior to database lock.  
9.3 Treatments  
All summaries describe d in this Section will be presented for subjects aged 16 to 35 years  and for all 
subjects  in the Safety Population .  
9.3.1  Extent of Study Drug Exposure  
The overall duration of total exposure  and actual exposure  will be summarized using descriptive statistics. 
In addition, the total extent of exposure  and total extent of actual exposure  across all subjects will be 
summarized  in years . 
Additionally, the number and percentage of subjects exposed for at least 26 weeks and at least 52 weeks  
based on actual exposure  will be presented. The denominators for calculating the percentages will be based 
on the number of subjects.  
The number of cycles as defined in Section 5.1 will also be summarized using descriptive statistics. The 
number and per centage of subjects who had at least 1, 2, 3, etc. cycles will be summarized.  
Exposure data will be listed for all subjects in the Safety Population.  
9.3.2  Treatment Compliance  
Treatment compliance by cycle  and overall  will be summari zed using descriptive stati stics including the 
following information:  
ÔÇ∑ The number of pills taken  
ÔÇ∑ The compliance   
The number and percentage of subjects missing no pills, 1 pill, 2 pills and more than 2 pills will be 
summari zed for each cycle  where the cycle is defined as per Section 5.1. The denominator will be the 
number of subjects in the Safety Population who started that cycle.  
The total number of pills taken across all subjects will be presented.  Compliance data will be listed for all 
subjects in the S afety Population.  Drug accountability data will be listed only in the Safety Population.  
9.3.3  Prior , Post -Study Treatment  and Concomitant Medications  
Medications received prior to or concomitantly with study drug, categorized by preferred term  according to 
WHOD RUG  Jun 2017 will be summarized  in the Safety Population . The number and percentage of subjects 
using each medication will be displayed.  This will be repeated for prior medications.  
All prior , post -study treatment  and concomitant medications will be listed  in the Safety Population . 
9.4 Demographic and Baseline Characteristics  
All summaries described in this Section will be presented for subjects aged 16 to 35 years  and for all 
subjects.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 27 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
The following demographic data  and baseline characteristics  will be summari zed in the ITT and PP 
Populations : 
ÔÇ∑ Age at Screening  
ÔÇ∑ Age group ( ‚â•16 to ‚â§25 years, >25 to ‚â§35 years, >35 to ‚â§50 years)  at Screening  
ÔÇ∑ Highest education level 
ÔÇ∑ Ethnicity  
ÔÇ∑ Race  
ÔÇ∑ Height  
ÔÇ∑ Weight at Baseline  
ÔÇ∑ BMI at Baseline  
ÔÇ∑ BMI categories (< 30kg /m2, ‚â•30kg/m2) at Baseline  
If subjects record more than one race, then for the summary  table , these subjects will be included in the 
Other Race group . BMI will be derived programmatically from the height and weight collected.  
The subject‚Äôs previous contraceptive method used will be summarized in terms of the number and 
percentage of switche rs, starters and true new users in the ITT Population.  Note: subjects who are true 
new users are a subset of the starters.  
The following information will be summarized for gynecological history in the ITT Population:  
ÔÇ∑ Gravidity and parity status  
ÔÇ∑ Menstrual c ycle length for starters  
ÔÇ∑ Dysmenorrhea  
ÔÇ∑ Previous contraceptive method used  
ÔÇ∑ History of pregnancy during accurate hormonal contraceptive use  
Smoking status , including the following information for current smokers  will be presented in the ITT 
Population :  
ÔÇ∑ The number of days per week where the subject smokes  
ÔÇ∑ The number of tobacco products per day that the subject smokes  
All demographic data , baseline characteristics , gynecological history, contraceptive use and smoking status  
will be listed  in the ITT Population . In the demography listing, if a subject has more than one race recorded, 
then all races selected will be listed for that subject.  
Medical history will be summarized in the ITT. Medical history will be classified into a standardized 
terminology using the Medical Dictionary for Regulatory Activities (MedDRA) system organ classifications 
and preferred terms. Version 20.0 of MedDRA will be used as coding dictionary.  
Surgical history will not be summarized.  
All medical and surgical history recorded will be li sted in the ITT Population . 
9.5 Efficacy Analyses  
9.5.1  Primary Variable  
The primary variable  will be  summarized using  the Pearl Index in the ITT population aged 16 to 35 years  
inclusive at Screening with at-risk cycles.  Subjects in this age group will not be censor ed on their 36th 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 28 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
birthday for the pregnancy assessment. The Pearl Index will be presented with corresponding 95% CIs. No 
formal statistical analyses will be conducted for the primary variable.  
The Pearl Index, defined as the number of pregnancies per 100 w omen -years of treatment, will be 
calculated as  
Pearl  Index = 1300  x number  of on‚àítreatment  pregnancies
number  of women ‚àí28 day equivalent  cycles  of treatment 
Only at-risk cycles will be included in the denominator of the Pearl Index calculation. At-risk cycles will be 
defined as cycles in which the following criteria are met:  
1. No other methods of birth control (including condoms and emergency contraception)  are used by 
the subject as confirmed in the subject diary  
2. The subject confirmed that sexual intercour se occurred during the cycle in the subject diary  
Note that if conception occurs in a cycle, then that cycle will be included as an at-risk cycle in the 
denominator even if other methods of birth control were used during that cycle or the subject did not c onfirm 
that they had had sexual intercourse. Cycles after the cycle of conception will  not be included as at-risk 
cycles and will  be excluded from the denominator.  
The number of women -28 day equivalent cycles of treatment is the sum of the number of at-risk cycles 
across all subjects.  The total number of at-risk cycles will be presented in the table.   
All on -treatment pregnancies will be included in the numerator for the Pearl Index (see Section 5.9.1  for 
definition of on -treatm ent pregnancies).  
For calculation purposes a cycle will be defined as per Section 5.1.1 .  
The 95% CI for Pearl Indices will be calculated using a Poisson distribution.  The confidence interval  limits  
are calculated by the following equation s: 
ùê∂ùêºùêøùëÇùëäùê∏ùëÖ =1300 √ó1
2ùúí0.025 ; 2ùë•2
ùë°‚Ñéùëí ùëõùë¢ùëöùëèùëíùëü  ùëúùëì ùë§ùëúùëöùëíùëõ ‚àí28 ùëëùëéùë¶  ùëíùëûùë¢ùëñùë£ùëéùëôùëíùëõùë°  ùëêùë¶ùëêùëôùëíùë†  ùëúùëì ùë°ùëüùëíùëéùë°ùëöùëíùëõùë°  
 
ùê∂ùêºùëàùëÉùëÉùê∏ùëÖ =1300 √ó1
2ùúí0.975 ; 2(ùë•+1)2 
ùë°‚Ñéùëí ùëõùë¢ùëöùëèùëíùëü  ùëúùëì ùë§ùëúùëöùëíùëõ ‚àí28 ùëëùëéùë¶  ùëíùëûùë¢ùëñùë£ùëéùëôùëíùëõùë°  ùëêùë¶ùëêùëôùëíùë†  ùëúùëì ùë°ùëüùëíùëéùë°ùëöùëíùëõùë° 
where x is the number of on -treatment pregnancies.  
The Pearl Index and corresponding 95% CIs will be presented by the subgroups described in Section 4.3 
for subjects aged 16 to 35 years . All subject diary data , pregnancy information and at-risk cycles for each 
analysis will be listed.  
9.5.2  Secondary Variables  
9.5.2.1  Pearl Index  
The Pearl Index and corresponding 95% CIs will be presented for all subjects in the ITT Population (see 
Section 9.5.1  for details)  including only at-risk cycles in the denominator . At-risk cycles will be defined as 
cycles in which no other methods of birth control (including condoms and emergency contraception)  are 
used by the subject as confirmed in the subject diary , and the subject confirmed that sexual intercourse 
occurred during the cycle in the subject diary.  The number of on -treatment pregnancies and at-risk cycles 
will be presented.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 29 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
The Pearl Index and corresponding 95% CIs will be  presented for subjects aged 16 to 35 years  and for all 
subjects in the ITT Population including all cycles in the denomin ator with the exception of c ycles after the 
cycle of conception in the case of pregnancy .  
The Pearl Index and corresponding 95% CIs w ill also be presented for subjects aged 16 to 35 years  and 
for all subjects in the ITT Population employing a modified at-risk definition. With this definition, at-risk 
cycles will be defined as cycles in which no other methods of birth control (including condoms and 
emergency contraception)  are used  by the subject  while cycles with and without confirmed intercourse are 
being included in the denominator .  
9.5.2.2  Method Failure Pearl Index  
The method failure Pearl Index is calculated using the same method as the Pe arl Index (see Section 9.5.1  
for details), but includes only those pregnancies that were classified as method failure (see Section 5.9.4  
for details). Pregnancies due to user failure will be exclude d from the numerator.  
The method failure Pearl Index and corresponding 95% CIs will be presented for subjects aged 16 to 35 
years  at Screening in the ITT Population and for all subjects in the ITT Population  including only at-risk 
cycles in the denominator . The number of on -treatment pregnancies and at-risk cycles will be presented . 
This will be derived in 4 ways:  
ÔÇ∑ Including all at-risk cycles in the denominator where at-risk cycles will be defined as cycles in which 
no other methods of birth control (includ ing condoms and emergency contraception)  are used by 
the subject as confirmed in the subject diary and the subject confirmed that sexual intercourse 
occurred during the cycle in the subject diary.  
ÔÇ∑ Including all at-risk cycles in the denominator  employing a  modified at-risk definition. With this 
definition, at-risk cycles will be defined as cycles in which no other methods of birth control 
(including condoms and emergency contraception)  are used  by the subject  while cycles with and 
without confirmed intercou rse are being included in the denominator.   
ÔÇ∑ Including only at-risk cycles in the denominator where at-risk cycles will be defined as cycles in 
which no other methods of birth control (including condoms and emergency contraception)  are 
used by the subject a s confirmed in the subject diary and the subject confirmed that sexual 
intercourse occurred during the cycle in the subject diary where the subject was compliant with the 
dosing rules  3 to 8 in Section 5.1.1 .  
ÔÇ∑ Including only modified at-risk cycles in the denominator where at-risk cycles will be defined as 
cycles in which no other methods of birth control (including condoms and emergency contraception)  
are used by the subject as confirmed in the subject diary where the subject w as compliant with the 
dosing rules  3 to 8  in Section 5.1.1  while cycles with and without confirmed intercourse are being  
included  in the denominator.   
9.5.2.3  Life-Table Rates  
In addition, the cumulative pregnancy rate, as determined b y life -table methods, together with the 
corresponding 95% CIs will be presented for all pregnancies and for all method failure pregnancies in the 
ITT population for all subjects  and for subject‚Äôs aged 16 to 35 years  inclusive at Screening.  
Life-table analy ses will provide one -year life -table pregnancy rates for each efficacy endpoint (i.e. for all 
pregnancies as used in the Pearl Index and for all method failure pregnancies as used in the method failure 
Pearl Index). The life -table analysis will evaluate th e cumulative probability of pregnancy by cycle using 
PROC LIFETEST in SAS where the time variable is the cycle where the estimated conception occurred for 
subjects who had an on -treatment event of pregnancy. Subjects who did not have an on -treatment event 
of pregnancy will be censored on the cycle prior to the cycle in  which they discontinued from the study. The 
rate of pregnancy and 95% CIs will be calculated based on Kaplan -Meier estimates for each cycle . 
Additionally, the estimated surviv al function agai nst time (cycle) will be provided.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 30 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
9.5.3  Bleeding and Spotting  
Bleeding patterns will be analyzed using data from the subject diary.  A cycle analysis and an analysis by 
RP will be performed (see Section 5.1.2  for details ). Derived da ta for bleeding and spotting will be listed in 
the ITT Population.  
9.5.3.1  Cycle Analysis   
The cycle analysis will be performed following two approaches: a classical (for details see Section 5.10.2.2 ) 
and a modified cycle analysis (fo r details see Section 5.10.2.3 ).  
The classical analysis will be performed in the ITT and PP Population. This analysis will also be repeated 
for the following populations:  
ÔÇ∑ The PP analysis excluding cycles where there is at leas t 1 day where an active pill was missed  
ÔÇ∑ The ITT analysis including only cycles where 1 active pill was missed  
ÔÇ∑ The ITT analysis including only cycles where 2 or more active pills were missed .  
The number of subjects with evaluable cycles for each population  will be summarized by cycle.  
The modified cycle analysis where early and continued withdrawal bleeding are classed as unscheduled 
bleeding  will be performed  in the ITT Population , PP Population and the PP Population excluding cycles 
where there is at lea st 1 day where an active pill was missed .  
Details of the exclusion of cycles from the PP Population are provided in Section 5.1.2 . Vaginal bleeding 
will be classified as spotting or bleeding and scheduled or un scheduled based on the definitions in Section 
5.10.1  and 5.10.2 . Rules for handling missing data are provided in Section 5.15.2 . The inclusion of cycles 
in ITT Population, PP Population and PP Population excluding cycles with at least 1 active pill missed in 
the cycle will be listed by subject and cycle along with reasons for exclusion of the cycle from the PP 
Population analysis  and the number of missed p ills. 
The following information will be summarized for bleeding and spotting for the cycle analysis : 
ÔÇ∑ Number and percentage of subjects with unscheduled bleeding and/or spotting episodes for each 
cycle (classical analysis  + modified cycle analysis ) 
ÔÇ∑ Number a nd percentage of subjects with unscheduled bleeding  only episodes for each cycle  
(classical analysis  + modified cycle analysis )  
ÔÇ∑ Number and percentage of subjects with unscheduled spotting  only episodes for each cycle  
(classical analysis  + modified cycle a nalysis )  
ÔÇ∑ Number and percentage of subjects with absence of  a scheduled bleeding and/or spotting  episode  
for each cycle  (classical analysis  + modified cycle analysis ) 
ÔÇ∑ Number and percentage of subjects with early withdrawal bleeding  and/or spotting  for each  cycle   
ÔÇ∑ Number and percentage of subjects with continued withdrawal bleeding  and/or s potting  for each 
cycle   
ÔÇ∑ Number and percentage of subjects with absence of any bleeding and/or spotting for each cycle   
ÔÇ∑ Descriptive statistics (e.g., mean, SD, median, mini mum, and maximum) for the number of days of 
bleeding and/or spotting, bleeding only, and spotting only within a cycle for  (classical and modified 
cycle analysis) : 
o Total Days (Unscheduled + Scheduled)  
o Unscheduled Days  
o Scheduled Days  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 31 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
ÔÇ∑ Cumulative number and pe rcentage of subjects with absence of withdrawal bleeding  and/or 
spotting  in the ITT Population only  (classical analysis)  
o The number of subjects who have no withdrawal bleeding and/or spotting  that started in at 
least 1 cycle, at least 2 cycles, at least 3 cycles and so on up to at least 13 cycles. The 
denominator is the number of subjects with at least 1 evaluable cycle, at least 2 evaluable 
cycles, at least 3 evaluable cycles and so on up to at least 13 evaluable cycles, 
respectively, for the specified pop ulation  
Note that the denominator for the percentages listed above will be the number of subjects with an evaluable 
cycle unless otherwise specified . 
The percentage of subjects with bleeding, the percentage of subjects with spotting and the percentage of 
subjects with absence of bleeding and/or spotting for each day will be presented in a bar chart over time 
for the ITT , PP Populations  and Populations based on active pill counts . The plot will start on Day 4 of Cycle 
1 because Days 1 -3 of Cycle 1 are not a ssigned to a shifted cycle so cannot be assigned to the specified 
analysis populations.  The 3 days imputed for the days included in shifted Cycle 13 after Day 28 of Cycle 
13 in the diary will not be included in the plot as these do not reflect the true ble eding pattern.  Day will be 
the day from the diary data i.e. pill intake days (examples: Day 4 = Cycle 1 Day 4 or Day 118 = Cycle 5 Day 
6). The denominator will be the number of subjects with an evaluable cycle for the specified population on 
that day.  
The descriptive statistics (e.g., mean, SD, median, minimum, and maximum) for the number of unscheduled 
bleeding and/or spotting  days , bleeding  days , and spotting days within a cycle will also be summarized in 
subjects who experienced  an unscheduled bleeding and/or spotting episode within that cycle. This will be 
presented for the classical and modified analysis in the ITT and PP Populations. Additionally, unscheduled 
bleeding and spotting and the absence of scheduled bleeding will be summarized for all subgro ups 
specified in Section 4.3 by cycle  for the classic cycle analysis for the ITT, PP Population and the PP 
Population excluding cycles with at least 1 missed active pill  and the modified cycle analysis for the I TT 
Population . 
The number and percentage of subjects with a scheduled bleeding episode starting on each day in the 
scheduled bleeding period in the shifted cycle (i.e. Day 25, 26, 27, 28 and Day 1, 2 and 3 of the next cycle 
in the diary) will be summarized  by Cycle. If there is more than one scheduled bleeding episode, then the 
only the earliest start date of the  scheduled bleeding episode s starting within the cycle  will be counted . This 
will be presented for the classical and modified analysis in the ITT P opulation.  
9.5.3.2  Reference Period Analysis  
All RP analysis will be performed in the ITT Population only . The following information will be summarized 
for bleeding and spotting for the RP analysis : 
ÔÇ∑ Descriptive statistics (e.g., mean, SD, median, minimum, and maxi mum) for the number of days of 
bleeding and/or spotting, bleeding only, and spotting only within a RP.  
ÔÇ∑ Descriptive statistics for the number of bleeding and/or spotting episodes in each RP  
ÔÇ∑ Descriptive statistics for the mean duration of the bleeding and/o r spotting episodes in each RP  
ÔÇ∑ Descriptive statistics for the number of bleeding and/or spotting free episodes in each RP  
ÔÇ∑ Descriptive statistics for the mean duration of the bleeding and/or spotting free episodes in each 
RP 
Note that the denominator for t he percentages listed above will be the number of subjects with an evaluable 
RP.  
The number of subjects with evaluable reference periods for each population will be summarized by 
reference period.  The inclusion of reference periods in ITT Population will be listed by subject and reference 
period along with reasons for exclusion of the reference period.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 32 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
9.6 Safety Analyses  
9.6.1  Adverse Events  
TEAEs will be classified into a standardized terminology using the MedDRA system organ classifications 
and preferred terms. Version  20.0 of MedDRA will be used as coding dictionary. The incidence of TEAEs 
will be summarized for the Safety Population.  
A summary of TEAEs  including the number of events reported , the annual rate and the number and 
percentage  of subjects reporting th e following will be presented:  
ÔÇ∑ Any TEAE  
ÔÇ∑ Any TEAE leading to death  
ÔÇ∑ Any treatment -emergent SAE  
ÔÇ∑ Any TEAE leading to premature discontinu ation from the study  
ÔÇ∑ Any SAE related to study medication  
TEAE s are defined in Section 5.11. The annual rate will be derived as the number of events divided by the 
total exposure across all subjects in years.  
A breakdown of the number and percentage of subjects reporting each TEAE  with the corresponding 
number of events , categorized by body system and preferred term coded according to the MedDRA 
dictionary, will be presented. Note that subjects are only counted once within each body system or preferred 
term but subjects with multiple events of a specific type will be counted once for each occurrence in the 
number of events column . 
A further tabulation of these data, categorized by relationship to study drug, will be presented. Subjects 
with multiple events within a particular body system or preferred term will be counted under the cate gory of 
their most drug -related event within that body system or preferred term  in column for the number of subjects . 
In the column for the number of events, multiple events of a specific type and relationship will be counted 
once for each occurrence.  Relationship to study drug is categorized as not related ( not related  and unlikely  
on the CRF) and related ( possible, probable and highly probable  on the CRF ). This will be repeated for 
TEAEs leading to premature discontinuation from the study.  
TEAEs  will also be presented  by severity . For each system organ class and preferred term, subjects are 
included only once, at the maximum severity . In the column for the number of events, multiple events of a 
specific type and severity  will be counted once for each occur rence.  
All adverse events (including non -treatment -emergent events) recorded on the CRF will be listed.  The 
following listings will be generated  in the Screen ed Population : 
ÔÇ∑ All AEs  
ÔÇ∑ AEs leading to premature discontinuation from the study  
9.6.2  Deaths and Serious  Adverse Events  
A tabulation of SAEs, categorized by relationship to study drug, will be presented. Subjects with multiple 
events within a particular body system or preferred term will be counted under the category of their most 
drug-related event within t hat body system or preferred term in column for the number of subjects. In the 
column for the number of events, multiple events of a specific type and relationship will be counted once 
for each occurrence. Relationship to study drug is categorized as  not related  (not related  and unlikely  on 
the CRF) and related  (possible, probable and highly probable on the CRF ).  
The following listings will be generated including non -treatment emergent events  in the Screened  
Population : 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 33 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
ÔÇ∑ All SAEs  
ÔÇ∑ All AEs leading to death  
ÔÇ∑ All SAEs related to treatment (includes SAEs where the relationship to study drug is possible, 
probable and highly probable)  
9.6.3  Laboratory Data  
Central laboratory data will be used for the tables and listings. The s cheduled laboratory assessments will 
be included in the tables  where data are available . If a specific parameter is missing at the scheduled 
assessment and there is an unscheduled assessment collected at the same visit where this parameter is 
not missing, then the value at the unscheduled assessment w ill be used in the table. Otherwise 
unscheduled assessments will not be included in the tables.  Note that  unscheduled pregnancy tests will be 
used in the assessment of pregnancies for the primary endpoint . The parameters listed in Table 4 will be 
summari zed. Separate outputs will be provided for hematology, serum chemistry and lipid profile.  
Table 4: Laboratory Parameters  
Hematology  
Hemoglobin  Mean cell volume  
Hematocrit  White blood cell & Differential  
Red blood cell count  Platelet count  
Serum Chemistry  
Albumin  Total protein  
Alanine aminotransferase (ALAT)  Serum creatinine  
Aspartate aminotransferase (ASAT ) Sodium  
Blood urea nitrogen  Potassium  
Gamma glutamyl transferase (GGT)  Calcium  
Glucose  Chloride  
Glycated hemoglobin  Bicarbonate  
Lactate dehydrogenase  (LDH) 1 and LDH 2   Phosphorus  
Total bilirubin  Choriogonadotropin Beta (Serum Pregnancy Test)  
Estimated Glomerular Filtration Rate (eGFR)   
Lipid Profile  
Total cholesterol  Triglycerides  
High density lipoprotein cholesterol  Low density lipoprotein cholesterol  
 
For continuous clinical laboratory analytes, the absolute value and change from baseline will be 
summarized by analyte and visit using descriptive statistics for th e Safety Population.  
Shifts to values outside of the normal range will be presented by analyte and visit and will be summarized 
by the number and percentage of subjects with evaluable shifts. The denominators for calculating the 
percentages will be the nu mber of subjects in the Safety Population with both the Baseline value and the 
value at the specified visit recorded . 
If the value is below the lower limit of quantification, then half the lower limit of quantification will be used in 
the summary tables to  calculate the descriptive statistics. If the value is above the upper limit of 
quantification, then the upper limit of quantification will be used in the summary tables to calculate the 
descriptive statistics . In the listings, v alues will be listed as col lected without the imputation applied.  
All clinical laboratory values, abnormal clinical laboratory values, and clinical significant laboratory values 
will also be provided in data listings  in the Safety Population  including data collected at any unschedu led 
assessments . 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 34 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
Chlamydia and gonorrhea test results will be listed.  
9.6.4  Vital Signs  
Unscheduled vital signs assessments will be excluded from the tables.  
Vital sign measurements (systolic blood pressure, diastolic blood pressure and heart rate) for the Safet y 
Population will be summarized using descriptive statistics by visit. The change from Baseline will also be 
summarized in the same manner.  
Weight and BMI measurements for the Safety Population will be summarized using descriptive statistics by 
visit. The change from Baseline will also be summarized in the same manner.  BMI will be derived 
programmatically from the height and weight collected.  
All vital signs, weight and BMI measurements will be listed  in the Safety Population  including data collected 
at any  unscheduled assessments . 
9.6.5  Physical  and Gynecological  Examinations  
Physical and gynecological examination assessments  will be summarized for the Safety population by visit. 
For each body system and assessment category, the number and percentage of subjects will be  presented. 
The denominators for calculating the percentages will be based on the number of  subjects evaluated for a 
particular body system.  Unscheduled physical examinations will not be summarized.  
All physical  and gynecological  examination data wi ll be listed  in the Safety Population . 
9.7 Other Secondary Endpoints  (Excluding PK)  
9.7.1  Quality of Life  
Quality of life data will be summarized in the ITT Population.  Summaries will be provided overall and by 
switchers and starters separately.  
For the Q -LES-Q-SF, the absolute values and change from baseline of the percentage maximum, how 
satisfied have you been with your medication and how would you rate your overall life satisfaction and 
contentment during the past week will be summarized descriptively by visit.  
For the Menstrual Distress Questionnaire, the absolute values and change from baseline for the scores for 
pain, water retention, autonomic reactions, negative affect, impaired concentration, behaviour change, 
arousal and control will be summarized descripti vely by visit  and by phase . The phases are menstrual (most 
recent flow), premenstrual (four days before) and intermenstrual (remainder of cycle).   
All quality of life data will be listed  in the ITT Population . 
9.7.2  Follow -Up Evaluations  
The number and percentag e of subjects who had pregnancy confirmation, return to menses and received 
a new contraceptive method  after discontinuation of study treatment  will be summarized. The denominator 
used for the percentages will be the number of subjects in the Safety Popula tion who discontinued study 
medication due to a pregnancy wish.  
The time from last dose of study medication to return of menses will be summarized using descriptive 
statistics in the Safety Population.  
The following  will be summarized using descriptive sta tistics  for subjects in the Safety Population who 
discontinue d study medication due to a pregnancy wish  who selected the corresponding fertility information:  
ÔÇ∑ Time from last dose of study medication to estimated date of conception  
ÔÇ∑ Time from last dose of st udy medication to new contraceptive method  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 35 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
The estimated date of conception is derived as the expected date of pregnancy term ‚Äì 38 weeks  (266 
days) .  
Data for follow -up evaluations will be listed for subjects in the Safety Population who discontinued study  
medication due to a pregnancy wish.  
9.8 Population Pharmacokinetics Analysis  
9.8.1  Data Included in Analysis  
Data from study MIT-Es0001 -C302  are very sparse (two samples at each of two visits per subject,  and 
collected relatively close together). These data alone will likely not support identification of many of the 
model parameters. To insure identifiability of parameters required to meet the objectives, rich data from 
study  Es0001 -C101  will be included in the data set. Additional data from study MIT -Es0001 -C103 m ay be 
included in the population PK analysis if relevant parameters are not identifiable with data from only MIT-
Es0001 -C302  and Es0001 -C101 .  
9.8.2  Objectives  
The objectives are  to assess the effect of various individual characteristics/covariates ( e.g., body w eight, 
race, smoking,  and fed vs fast ed status) on the pharmacokinetics (PK) of 15 mg Estetrol (E4)/3 mg 
Drospirenone (DRSP).  As data permit, PK parameters will include, but are not limited to:  
ÔÇ∑ Primary parameters (i.e. model parameters):  
o Apparent clearance  (CL/F).  
o Central volume of distribution (V/F).  
o Lag time of Absorption ( Tlag), if necessary.  
o Relative bioavailability for fed vs fasted state . 
ÔÇ∑ Secondary parameters (i.e. derived parameters ): 
o Maximum concentration (Cmax).  
o Time to Cmax (Tmax).  
o Extent of expos ure for the dosing interval (AUC tau) at steady state.  
o Terminal half -life (t ¬Ω). 
o Predicted trough drug concentration (Ctrough)  at steady state . 
o Distribution half -life (t ¬Ω) (if applicable) . 
9.8.3  Assumptions  
Missing covariates will be imputed as the most recent rep orted value (last value carried forward) if any are 
reported for that subject. If no value is available, missing covariates will be imputed as the median of all 
other subjects  within the study . 
Patients will record time of the most recent dose prior to sam ple collection. This dose will be assumed to 
be at steady state, with a 24 -hour dosing interval.  
Two separate models will be developed, one for E4 and one for DRSP. It is assumed these drugs do not 
interact.  
9.8.4  Prespecified Hypotheses  
Pre-specified hypothes es will be tested before any hypotheses that are based on diagnostic plots. Formal 
conclusions will be drawn only from these prespecified hypotheses. Results of other hypotheses (e.g., those 
based on diagnostic plots) will be considered exploratory  and wil l not lead to conclusions .  
1. Effect of body weight on volume of distribution of E4.  
2. Effect of body weight on clearance of E4  
3. Effect of race on clearance for E4.  
4. Effect of smoking status on clearance for E4.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 36 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
5. Effect of fed vs fasted state on rate (e.g. Ka) or  extent (e.g., F) of absorption for E4.  
6. Effect of body weight on volume of distribution of DRSP.  
7. Effect of body weight on clearance of DRSP  
8. Effect of race on clearance of DRSP.  
9. Effect of smoking status on clearance of DRSP.  
10. Effect of fed vs fasted state o n rate (e.g. Ka) or extent (e.g., F) of absorption for DRSP . 
 
9.8.5  Study MIT -Es0001 -C302  
A Multicenter, Open -label, Single -Arm Study to Evaluate the Contraceptive Efficacy and Safety of a 
Combined Oral Contraceptive Containing 15 mg Estetrol and 3 mg Drospiren one. 
 
Two PK samples will be taken from the subjects in the Population PK Substudy at Visits 3 and 4. All subjects 
included in the Substudy will provide a sample for PK analysis at the time they check into the site (PK 
sampling 1). An additional blood samp le (PK sampling 2) will be collected approximately two hours after 
the first sample.  
 
The following timings will be recorded by the site personnel in the eCRF:  
- The exact times of the last study medication dosing and the PK samplings 1 and 2.  
Depending on  the time scheduled for the study site visit (Visit 3 & 4), subjects were instructed on 
when they need to take their medication ‚Äì either as usually done at home or on site. One blood 
sample will be taken before dosing and the second blood sample will be ta ken within 2 -hour 
postdose. The subjects were instructed to record the time of the dosing in the Diary.  
 
- The time of the last meal intake before the last study medication dosing before study visit.  
9.8.6  Study Es0001 -C101  
A study to characterize the effect of food on the bioavailability of 15 mg Estetrol/3 mg Drospirenone 
tablets in healthy female volunteers.  
 
Es0001 -C101 was an open -label, randomized, balanced, single -dose, two -treatment, two -period, two -
sequence crossover study conducted under medical supervi sion in 28 healthy female volunteers. All 
subjects entered the study site at least 12 hours before each dosing and fasted for at least 10 hours prior 
to each dose. All subjects received the following 2 treatments:  
ÔÇ∑ Treatment A (Reference): a single 15 mg E4 /3 mg DRSP tablet without food (fasted).  
ÔÇ∑ Treatment B (Test): a single 15 mg E4/3 mg DRSP tablet with food (fed).  
All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or the 
second treatment period (Period 2 ). Approximately half of the subjects were randomized to receive either 
Treatment A followed by Treatment B (Sequence AB), or Treatment B followed by Treatment A (Sequence 
BA) as described in Table 5. 
PK Sampling: Blood samples were collected prior to each  dose and at 10, 20, 30 and 45 min, and then at 
1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 , and 72 hours post -dose for pharmacokinetic (PK) 
analysis.  
Table 5.  Treatment Sequences  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 37 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
Sequence  Period 1  Period 2  
AB  Treatment A: 1 tablet 15 m g 
E4/3 mg DRSP in fasted conditions  Treatment B: 1 tablet 15 mg 
E4/3 mg DRSP in fed conditions  
BA Treatment B: 1 tablet 15 mg 
E4/3 mg DRSP in fed conditions  Treatment A: 1 tablet 15 mg 
E4/3 mg DRSP in fasted conditions  
 
9.8.7  Study MIT -Es0001 -C103  
A Randomize d, Double -Blind, Placebo -Controlled, Parallel, Single Center Study To Investigate The 
Pharmacokinetics, Safety, Tolerability, And QT Concentration -Effect Modelling Of Estetrol (E4) In 
Combination With Drospirenone (DRSP) After Single And Multiple Dosing In  Healthy Women.  
 
MIT Es0001 -C103 was a randomized, double -blind, placebo -controlled, parallel, single and multiple oral 
dose study to investigate the PK, safety and tolerability of therapeutic and supratherapeutic single and 
multiple doses of E4 in combina tion with DRSP in healthy female subjects. A total of 42 healthy female 
subjects were to be enrolled in 3 groups of 14 subjects each.  
Subjects  receive d a single dose on Day 1 and after washout of at least 14 days, multiple doses during 14 
consec utive days from Days 15 to 28.  
 The following treatments  in Table 6 were  administered:  
Table 6.  MIT-ES0001 -C103 Treatments  
 Dose Level E4 (mg)  Dose Level DRSP 
(mg)  Dosage  
Group 1  15  3 Therapeutic E4/DRSP 
dose level  
Group 2  30 6 2 times therapeutic 
E4/DRSP dose l evel 
Group 3  60 12 4 times therapeutic 
E4/DRSP dose level  
E4 = Estetrol ; DRSP = Drospirenone.  
Drug administration on Days 1 and 28 were  under fasted conditions. Drug administration on Days 15 to 27 
were  at the same time of day as on Days 1 and 28, witho ut regard to meals; however, subjects will be 
fasted before all clinical laboratory assessments.  
PK sampling:  Samples for pharmacokinetic analysis were collected at the following times:  
On Day 1 and Day 28: at pre -dose and at 15 and 30 minutes and 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 
96, 120, 144, and 168 hours post -dose.  
On Days 17, 19, 21, 23, 25 and 27: at pre -dose.  
9.8.8  Data management  
A NONMEM data set will be created from source data files provided by PRA for study MIT -Es0001 -C302 
and by Estetra  for Es0001 -C101 and (if used) MIT-Es0001 -C103  and will undergo quality control (QC) 
review according to SOPs at the time of the finalization of the analysis plan.  
The data manager will create one or more code files to automate the process of formatting th e source 
dataset into the popPK dataset. No manual editing of the data will be done. The code file for the creation 
of the popPK datasets will be in R version 3.3.1 or later (R Foundation for Statistical Computing, Vienna, 
Austria).  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 38 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
A popPK data set can b e very large. QC of the final NONMEM dataset will include manual comparison of 
a subset of the records to the source data (Sponsor or PRA provided dat asets) as well as diagnostics on 
the entire dataset to identify errors. Diagnostics will also be performed  to ensure that the dataset complies 
with the formatting standards for NONMEM. The QC may include review of the code used to generate the 
dataset, as appropriate. This QC will be done by personnel other than the data manager. Any discrepancies 
will be addr essed. Revised datasets will undergo quality control to confirm that the expected changes (e.g., 
deleted data records) are correct. The scope of the QC will be dependent on the nature and complexity of 
the study, as well as the source data. Any unique or c omplicated formatting issues associated with the 
dataset will be flagged by the data manager for specific QC review.  
9.8.9  Data Deletion  
9.8.9.1  Missing Data  
Incomplete data (e.g., missing dosing times) is a frequent occurrence in population analysis data sets. 
Typical ly, data with a missing or clearly erroneous dose time will be imputed per protocol or deleted  as 
appropriate .  
9.8.9.2  Erroneous Data  
Data in the Sponsor data set will occasionally be found to be inconsistent with the known pharmacokinetics 
of the drug or study procedures. These may be a result of recording errors in the database (e.g., dose 
administered prior to study start or after study completion) or unrealistic pharmacokinetic considerations. 
These data may be deleted if they cannot be corrected based on dat a review and site queries.  
9.8.9.3  Outliers  
Outliers will be distinguished from erroneous data as being unusual but not inconsistent with the known 
pharmacokinetics of the drug. Outlier data may include entire subjects, entire subject visits, or individual 
obser vations. Outliers will be deleted only after careful examination of possible causes.  
9.8.10  PopPK Model Development  
Population pharmacokinetic model development will be performed in compliance with SOPs at the time of 
the finalization of the analysis plan.  
9.8.10.1  Data  Set Creation  
Prior to initiation of analysis, NONMEM and other population PK software require specifically formatted data 
sets. Creation of these data sets is addressed Section 9.8.6 .  
9.8.10.2  Handling Data below the Limit of Quantifi cation (BLQ)  
BLQ data will be handled according to the ‚ÄúM3‚Äù methodology ( Beal, 2001 ). 
9.8.10.3  Model Development Procedures  
A Bayesian analysis will be used to fit concentration -time data. Model features (number of compartments, 
lag times, covariate effects) will be included based on goodness of fit statistics (e.g., log -likelihood) and 
diagnostic plots. Th ese pharmacokinetic models will be evaluated and used to derive individual post hoc 
pharmacokinetic parameters for E4 and DRSP desc ribed in Objectives ( 9.8.2 ).  
Initial estimates of PK parameters (e.g., CL/F, V/F, Tlag) will be determined using exploratory 
compartmental analyses or previous PK analysis. These estimates will be employed to build an appropri ate 
population PK model. The impact of individual characteristics on the PK parameters will be explored and 
included in the population model if significant.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 39 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
9.8.11  PopPK Model Evaluation  
A traditional approach  to model selection will be used. In this approach, an initial simple model is run. 
Additional features are sequentially added to this model (e.g., compartments, lag times, variance terms, 
covariates), testing each addition for statistical significance, improvement of diagnostic graphics and/or 
biological p lausibility. Model features (e.g., lag times, compartments) will be added or removed based on 
evaluation of diagnostic plots, consideration of biological plausibility, and statistical tests. The goodness -
of-fit between hierarchical models is measured by th e difference in the objective function value (OFV) 
produced by NONMEM. The difference in OFV between two hierarchical or nested models is approximately 
œá2 distributed, with n degrees of freedom. As such, the OFV is used to obtain the significance level for  the 
difference between two nested models. The criteria for forward addition will be p<0.05 and the criteria for 
backward elimination will be p<0.001. Covariate analyses will be performed separately for the PK of E4 and 
DRSP.  
Assessment of model adequacy a nd decisions about increasing model complexity will be driven by the data 
and guided by goodness -of-fit criteria, including:  
1. Visual inspection of diagnostic plots ( e.g.,observed vs. predicted concentration, residual/weighted 
residual versus predicted c oncentration or time , and histograms of individual random effects).  
2. Successful convergence of the minimization routine with at least 2 significant digits in parameter 
estimates. Successful minimization and covariance steps will be desired, but not requ ired. 
3. Plausibility of parameter estimates.  
4. Precision of parameter estimates, if available.  
5. Correlation between model parameter estimation errors < 0.95.  
6. Likelihood ratio test.  
7. Asymptotic and or Bootstrap estimate of confidence interval f or parameter estimates . 
Covariates to be considered during population pharmacokinetic model building include, but are not limited 
to, variables such a s body weight,  race, smoking, and fed vs fasted status . Pre -specified hypo theses will 
be examined first, f ollowed by hypotheses generated from diagnostic plots. If applicable, this will be followed 
by an automated covariate search ( SCM user guide ). 
9.8.11.1  Visual Predictive Check  
In order to verify that the final model adequately predic ts both the central tendency and the variability of the 
observed data, a visual predictive check (VPC) stratified by weight, race, smoking status , and fed/fasted 
status will be performed. VPC plots will be made for two or three strata for weight and each stratum for the 
categorical covariates. For the VPC, simulations will be performed using the final model and final model 
parameters. The original data set will be used as a template for simulation input. Simulations will be 
performed to generate approximate ly 1,000 simulated observations at each time point; if 1,000 simulated 
observations are not feasible based on the model run times, a reduced number of simulated observations 
will be used. A graphical comparison will be made between the observed data and th e model predicted 
median and 95% prediction interval over time. Additional VPC plots may be generated to include confidence 
intervals for the median and prediction intervals of the simulated data. VPC will be conducted in PsN and 
the result will be summari zed using Xpose ( Jonsson and Karlsson, 1999 ). 
9.8.12  Reporting  
A submission ready report will be developed, as described below.  
9.8.12.1  Report Structure  
The popPK report will comprise the following sections:  
1. Summary  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 40 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
2. Objectives and Hypothes es  
a. Statement of the objectives of the analysis and formal statement of any hypotheses to be 
tested.  
3. Assumptions  
a. List of assumptions, with supporting data, as applicable. Assumptions will not be formally 
tested.  
4. Materials and Methods  
a. Data: description of data, to include (as applicable and appropriate) the number of 
individuals, number of observations, and range of sample collection times.  
b. Data analysis methods:  
i. The methods (e.g., forward addition/backward elimination) and criteria for model 
selection (li kelihood ratio test, diagnostic plots).  
5. Results  
a. PopPK results  
i. Data description: summary statistics including mean, median, and SD of 
continuous covariates, and distributions of discrete covariates.  
ii. Description of base model, including parameter estimates  and model 
qualification/diagnostic plots.  
iii. Description of final model, including parameter estimates and model 
qualification/diagnostic plots.  
6. Conclusion  
Conclusions will be based on pre -specified hypotheses only. Hypotheses generated during 
analysis (e. g., from diagnostic plots) will be considered exploratory only.  
7. Discussion  
8. Figures  
a. Figures supporting model selection decisions will be included in the report.  
b. Typical diagnostic plots will include Conditional  Weighted Residuals vs. Time , vs. 
Conditional  Weighted Residual s vs.  Prediction, and Observed Dependent Variable vs. 
Prediction/Individual Prediction.  
c. VPC (Visual Predictive Check).  
d. Histogram of post hoc ETAs.  
e. Observed values vs. individual predicted values.  
f. Observed values vs . population predicted values . 
9.8.13  Source Files  
The following documents will be provided as ASCII text files based on the final analysis:  
a. Source data used in the analysis (NONMEM data set).  
b. Base model control file.  
c. Base model output file.  
d. Final Model control file.  
e. Final model output  file. 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 41 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
10.0 Validation  
PRA's goal is to ensure that each TFL delivery is submitted to the highest level of quality. PRA‚Äôs quality 
control procedures will be documented separately in the study specific Quality Control Plan.  
11.0 References  
Beal S. L. Ways to fit a P K model with some data below the quantification limit. J Pharmacokinet 
Pharmacodyn 28(5), 481 -504 (2001).  
Gerlinger, C., Endrikat, J., van der Meulen, E. A., Dieben, T. O. & Dusterberg, B. Recommendation for 
confidence interval and sample size calculation for the Pearl Index. Eur.J.Contracept.Reprod.Health Care 
8, 87 -92 (2003).  
Jonsson E.N and Karlsson M.O. Xpose --an S-PLUS based population pharmacokinetic/  pharmacodynamic 
model building aid for NONMEM. Comput Methods Programs Biomed. Jan;58(1):51 -64 (1999) . 
Moos, R. H. The development of a menstrual distress questionnaire. Psychosom Med 30, 853 -867 (1968).  
SCM user guide http://psn.sourceforge.net/pdfdocs/scm_userguide.pdf. Accessed 18 August 2016.  
12.0 Amendment to the Statistical Analysis Plan  
12.1 Amendment 1  from SAP dated 12 December  2016 
The key changes to the SAP in amendment  1 are as follows : 
ÔÇ∑ Missing data rules moved to one section for missing data  
ÔÇ∑ The addition of analyses for the Pearl Index to look at the rate of on-treatment pregnancies  and 
on-treatment met hod failure pregnancies  where the at-risk cycles are defined as cycles in which 
no other methods of birth control are used by the subject  
ÔÇ∑ The addition of a n analysis for the Pearl Index to look at the rate of method failure on -treatment 
pregnancies excludi ng at-risk cycles that were not compliant according to Section 9.4.4 of the 
protocol  
ÔÇ∑ Clarification of the definition of the evaluable cycles for the bleeding analysis in the PP Population 
in cases where the post Screening biopsy was not performed during Cy cle 13  
ÔÇ∑ Addition of criteria for exclusion from the PP Population to exclude cycles within 28 days after 
prohibited mediations  
ÔÇ∑ Clarification that the Baseline value for the Menstrual Distress Questionnaire is the value 
collected at Visit 3 as the date of co llection is not collected  
ÔÇ∑ Clarification added that compliance by cycle will be based on the cycles defined from the start 
dates of the cycles per Section 5.1 including detail on how gaps between cycles and overlapping 
cycles ar e handled  
ÔÇ∑ Clarification added that for overall compliance only pills reported between the start and stop date 
for study medication will be included in the numerator  
ÔÇ∑ The addition of actual exposure accounting for days where no pills were taken  
ÔÇ∑ Addition of t he number of subjects with bleeding only episodes and spotting only episodes by 
cycle as endpoints  
ÔÇ∑ Change in the definitions of unscheduled and scheduled bleeding and spotting days to use the 
episodes  
ÔÇ∑ Clarification added for imputation for missing bleedin g data to cover scenarios where 3 or more 
days having missing data at the end of the diary data collected  
ÔÇ∑ The definition of an evaluable reference period was updated to exclude reference periods where 
there are gaps between the cycles  
ÔÇ∑ Cumulative absence of  withdrawal bleeding  rate added as an endpoint  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 42 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
ÔÇ∑ Bleeding analysis section restructured and split out in to the  classical cycle analysis (including 
early and continued withdrawal bleeding as scheduled) which is now classed as the primary 
definition and the mo dified analysis (including early and continued withdrawal bleeding as 
unscheduled) which is no longer classed as the primary definition  
ÔÇ∑ Analyses of bleeding data added for cycles with exactly 1 missed active pill and for cycles with at 
least 2 missed activ e pills  
ÔÇ∑ The bleeding analysis by reference period was simplified to no longer differentiate between 
scheduled and unscheduled bleeding  
ÔÇ∑ Clarification on the scales derived for the Menstrual Distress Questionnaire added  
ÔÇ∑ Enrolled Population definition correc ted to use the enrollment date  
ÔÇ∑ PP Population corrected to make it clear that only the PP Population for bleeding is being derived  
ÔÇ∑ Reference to ATC classification removed as data are not coded to ATC in this study  
ÔÇ∑ Clarification added to indicate that BMI w ill be programmatically derived from height and weight 
for the vital signs and demography tables  
ÔÇ∑ Listing added for the at-risk cycles for each Pearl Index analysis  
ÔÇ∑ Clarification added to categorize relationship to study medication as not related and relate d for 
AEs 
ÔÇ∑ Change to  the handling of unscheduled laboratory assessments and clarification added for values 
above the upper limit of quantification and values below the lower limit of quantification  
ÔÇ∑ Choriogonadotropin beta and eGFR added as laboratory parame ters to be summarized  
ÔÇ∑ Addition of summaries and listings of evaluable cycles and reference periods for the bleeding 
analysis  
ÔÇ∑ Bleeding and spotting analysis section moved to Section 9.5  
ÔÇ∑ Correction to the definition of the alternative definition of at-risk cycles that will be used for the 
derivation of the Pearl Index for method failure pregnancies based on compliance to indicate that 
all 8 criteria need to be met for a cycle to be at-risk 
ÔÇ∑ Correction to definition of the presence of a bleeding only unschedu led episode and the presence 
of a spotting only unscheduled episode for the cycle analysis for bleeding  
ÔÇ∑ Addition of a section for missing or partial dates for AEs  
ÔÇ∑ Addition of a new analysis of the method failure Pearl Index i cluding only modified at-risk cycles in 
the denominator where at-risk cycles will be defined as cycles in which no other methods of birth 
control (including condoms and emergency contraception)  are used by the subject as confirmed in 
the subject diary where the subject was compliant wit h the dosing rules  3 to 8  in Section 5.1.1  while 
cycles with and without confirmed intercourse are being included in the denominator  
ÔÇ∑ Clarification added on how to handle pregnancies for the at-risk cycles when the cycle is not in the 
diary data  
ÔÇ∑ Clarification added on the handling of partial dates in the diary data  
ÔÇ∑ Addition of summary tables of unscheduled bleeding and spotting days in subjects who had 
unscheduled bleeding and/or spotting episodes  
ÔÇ∑ Clarification added that the exc lusion  of cycles  for unauthorized medications may be different 
between the bleeding analysis and contraceptive efficacy  
ÔÇ∑ Clarification added on the inclusion of subjects with an on -treatment or post treatment pregnancy 
but no diary data in the Safety Popula tion and rules were added on how to derive the start and stop 
dates for those subjects  
ÔÇ∑ Clarification added that if the subject has an on -treatment pregnancy, then the On -Treatment 
Period for efficacy ends on the estimated date of conception for that subje ct  
ÔÇ∑ Addition of summary tables for the number of subjects with a scheduled bleeding episodes starting 
on each day in the cycle for the classical and modified cycle analysis for bleeding data  
ÔÇ∑ Clarification added that the day for figures of bleeding by day will be the day in the diary data as 
collected  
ÔÇ∑ WHO drug dictionary version updated  
ÔÇ∑ Update to the prior medications definition for contraceptives  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 43 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
12.2 Amendment 2 from SAP dated 13 November 2018  
ÔÇ∑ Update in the definition for TEAEs to be consistent with the protoc ol and include all AEs starting on 
or after the date of first dose of study medication  
  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 44 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
Appendix 1  Glossary of Abbreviations  
Glossary of Abbreviations:  
AE Adverse Event 
ALAT  Alanine Aminotransferase  
ASAT  Aspartate Aminotransferase  
AUC  Area under the c urve 
AUC tau Extent of exposure for the dosing interval  
BLQ  Below the Limit of Quantification  
BMI Body Mass Index  
CI Confidence Interval  
CL Clearance  
Cmax  Maximum concentration  
COC  Combined Oral Contraceptives  
CRF Case Report Form  
CTMS  Clinical Tri als Management System  
DRSP  Drospirenone  
E4/3 Estetrol  
eGFR  estimated Glomerular Filtration Rate  
GGT  Gamma Glutamyl Transferase  
IC Informed Consent  
ITT Intention -to-Treat  
LDH Lactate dehydrogenase  
LOCF  Last Observation Carried Forward  
max Maximum  
MedDRA  Medical Dictionary for Regulatory Activities  
min Minimum  
n Number of subjects  
NONMEM  Nonlinear mixed effects model  
OFV Objective function  value  
PD Pharmacodynamics  
PK Pharmacokinetics  
PP Per Protocol  
Q1 25th percentile or lower quartile  
Q3 75th percentile or upper quartile  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 45 of 45 
Strictly Confidential. ¬© 2004 -2014, PRA  Health Sciences. All rights reserved.  
Q-LES-Q-SF Quality of Life Enjoyment and Satisfaction Questionnaire Short Form  
RP Reference Period  
SAP Statistical Analysis Plan  
SAE Serious Adverse Event  
SD Standard Deviation  
SEM  Standard Error of the Mean  
Tlag  Lag time of absorption  
TEAE  Treatment -Emergent Adverse Event  
TFL Tables, Figures and Listings  
Tmax  Time to maximum concentration  
Vc Central Volume of distribution  
V/F Central volume of distribution  
VPC Visual predictive check  
 